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Abstract 
  Mammalian cells use a variety of molecules to receive, process, and transmit 
information from the extracellular environment. Proteins receive and transmit signals 
through direct protein-protein interaction at the membrane surface and within the 
cytoplasm.  Similarly, membrane lipids facilitate signal transmission across the 
membrane by direct interaction with intracellular proteins. In this disertation, I have 
investigated protein-protein and lipid-protein interactions of important signaling 
molecules by employing biochemical methods and novel single-molecule approaches.  
  Mammalian target of rapamycin (mTOR) is a master regulator of mammalian cell 
growth and proliferation. Phosphatidic acid (PA) is a critical mediator of mitogenic 
activation of mammalian target of rapamycin complex 1 (mTORC1) signaling, a master 
regulator of mammalian cell growth and proliferation. However the mechanism by which 
PA activates mTORC1 signaling has remained unknown. In Chapter I of my thesis, I 
discovered a new mechanism by which the lipid second messenger phosphatidic acid 
(PA) regulates mTORC1 complex. PA competes with the mTORC1 inhibitor, FK506 
binding protein 38 (FKBP38), for mTOR binding at a site encompassing the rapamycin-
FKBP12 binding domain. This leads to PA antagonizing FKBP38 inhibition of mTORC1 
kinase activity in vitro and rescuing mTORC1 signaling from FKBP38 in cells. 
Additionally, PA binding to mTORC1 leads to an increase in kinase activity by an 
allosteric effect, independently of FKBP38. In conclusion, a dual mechanism for PA 
activation of mTORC1 is proposed– PA displaces FKBP38 from mTOR and 
allosterically stimulates the catalytic activity of mTORC1. 
mTOR functions as part of either of the two multisubunit complexes, mTORC1 
and mTORC2, but molecular details about the assembly and oligomerization of mTORCs 
are currently lacking.  In chapter III of my thesis, in collaboration with Dr. Ankur Jain 
from Dr. Taekjip Ha laboratory, I used the single-molecule pulldown (SiMPull) assay to 
investigate the stoichiometry and assembly of mTORCs. After validating this novel 
approach with mTORC1, confirming a dimeric assembly as previously reported, I show 
that all major components of mTORC2 exist in two copies per complex, indicating that 
mTORC2 assembles as a homodimer. Interestingly, each mTORC component, when free 
from the complexes, is present as a monomer and no single subunit serves as the 
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dimerizing component. Instead, the data suggest that dimerization of mTORCs is the 
result of multiple subunits forming a composite surface. SiMPull also allowed the 
distinction of complex disassembly from stoichiometry changes. Physiological conditions 
that abrogate mTOR signaling such as nutrient deprivation or energy stress did not alter 
the stoichiometry of mTORCs. On the other hand, rapamycin treatment leads to transient 
appearance of monomeric mTORC1 before complete disruption of the mTOR–raptor 
interaction, whereas mTORC2 stoichiometry is unaffected. These insights into assembly 
of mTORCs may guide future mechanistic studies and exploration of therapeutic 
potential. 
              Signaling phospholipids are critical mediator of biological processes such 
as cell growth, proliferation, and metabolism. Recognition of signaling 
phospholipids by proteins is important for the targeting and initiation of many 
signaling cascades, but the mechanisms that regulate such interactions are not 
completely understood. The majority of the biophysical methods used to measure 
these interactions are performed with pure proteins in-vitro. In Chapter IV, in 
collaboration with graduate student Vasudha Aggarwal from Dr. Taekjip Ha 
laboratory, I have developed a single-molecule fluorescence approach to analyze 
lipid-protein interaction using crude cell extracts. The assay is applicable to a 
variety of lipid-binding domains (LBDs) expressed in cell lysates, and these LBDs 
are specifically pulled down by their target phospholipids. The single-molecule 
analysis quantitatively describes the interaction of LBDs on the lipids in real-time. 
These allowed the distinction of assembly features and kinetics for the different 
LBDs uncovering novel interaction behaviors. As an extension to cellular 
proteins, I determined the assembly properties of protein kinase Akt. Overall, this 
study demonstrates the strength of our assay to investigate protein-lipid interaction 
mechanisms in a new light.    
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CHAPTER I  
Introduction 	  
 
I.1. Mammalian target of rapamycin (mTOR) 
 Eukaryotic cells have acquired complex regulatory mechanisms that monitor 
nutrient and energy levels to regulate cell growth and division. An evolutionarily 
conserved protein from yeast to mammals called target of rapamycin (TOR), is a key 
regulator of these processes. Mammalian TOR (mTOR) integrates the sensing of 
nutrients, growth factors, oxygen, energy and cellular stress to regulate a myriad of 
processes such cell growth, proliferation and survival (Fig. I. 1). Accordingly, 
misregulation of mTOR activity is implicated in genetic diseases (Inoki, Corradetti et al. 
2005), cancer (Guertin and Sabatini 2007), obesity, diabetes (Dann, Selvaraj et al. 2007; 
Vodenik, Rovira et al. 2009), and lifespan extension (Harrison, Strong et al. 2009; 
Selman, Tullet et al. 2009; Stanfel, Shamieh et al. 2009) (Fig. I. 2). Therefore, it is 
important to understand in molecular detail how mTOR signaling network works.  Such 
understanding may aid in the development of disease treatment and drug design. 
mTOR is a 290 kDa serine/threonine protein kinase that belongs to the PI3K 
related kinases family (PIKK) (Keith and Schreiber 1995). Other members of this family 
include the kinases ATM, ATR, DNA-PK, SMG-1, and TRRAP (Baretic and Williams 
2014).  All members of this family share a similar domain composition: a kinase domain 
that is functional in all members except for TRRAP (McMahon, Van Buskirk et al. 
1998); a short FATC domain, present at the C-terminus of the kinase domain; a helical 
solenoid FAT domain just N-terminal to their kinase domain; and HEAT (huntinting, 
elongation factor 3, A subunit of PP2A, TOR) repeats. HEAT repeats are rod-like helical 
domains involved in protein-protein interactions and intracellular transport. Interestingly, 
only mTOR has an FRB (FKBP12 rapamycin binding) domain. As implied, FRB is the 
binding site for the drug rapamycin when complexed with the protein FKBP12. FRB 
serves as the binding site for the lipid second messenger phosphatidic acid (PA) (Fang, 
Vilella-Bach et al. 2001) and is part of the binding site for FKBP38, a negative regulator 
of mTOR signaling (Bai, Ma et al. 2007) (Fig. I. 3). Although all the members share 
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structural similarities and domain composition, they participate in distinct cellular 
processes. Among them,. mTOR is the only member that responds to nutrients and 
hormone signals. 
I.2. Rapamycin 
Rapamycin is a natural product produced by Streptomyces hygroscopicus. It was 
first discovered on Eastern Island as a potent fungicide (Vezina, Kudelski et al. 1975; 
Singh, Sun et al. 1979). Subsequently, it was found to have immunosuppressive activity 
and anti-tumor activity (Eng, Sehgal et al. 1984). The molecular target of rapamycin, 
TOR, was first identified in yeast (Heitman, Movva et al. 1991; Sabatini, Erdjument-
Bromage et al. 1994). Due to its exceptional specificity and potency towards mTOR, 
rapamycin has been an invaluable tool in dissecting the biological functions of this 
protein. Rapamycin is even an FDA approved drug for organ transplantation 
immunosuppression and certain types of cancer. Rapamycin is known to limit substrate 
access to the kinase domain (McMahon, Choi et al. 2002; Yang, Rudge et al. 2013) as 
well as induce raptor dissociation from mTOR (Kim, Sarbassov et al. 2002; Oshiro, 
Yoshino et al. 2004; Yip, Murata et al. 2010). Rapamycin is also known to displace key 
activators of mTOR, thereby inhibiting downstream signaling (Fang, Vilella-Bach et al. 
2001). 
 
I.3. mTOR complexes, biological functions and regulation 
 mTOR nucleates two biochemically and functionally distinct complexes, 
mTORC1 and mTORC2 (Fig. I. 4). mTORC1 is composed of the proteins Raptor, 
mLST8/GBL, (Hara, Maruki et al. 2002; Kim, Sarbassov et al. 2002; Kim, Sarbassov et 
al. 2003), and the regulatory proteins PRAS40 and Deptor, which function as inhibitors 
of mTORC1 (Sancak, Thoreen et al. 2007; Peterson, Laplante et al. 2009). mTORC1 
regulates cell growth and proliferation and its activation depends on nutrient (in particular, 
amino acids) availability and growth factors (Dunlop and Tee 2009). The best-known 
substrates of the mTORC1 kinase are the ribosomal subunit kinase S6K1 and the eIF4E 
binding protein 4EBP1 (Brown, Beal et al. 1995; Burnett, Barrow et al. 1998). When 
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phosphorylated by mTORC1, these proteins regulate translation initiation and ribosome 
biogenesis. mTORC1 function is specifically inhibited by rapamycin. 
 mTORC2 consists of Rictor, mLST8, mSIN1 (Sarbassov, Ali et al. 2004; Frias, 
Thoreen et al. 2006; Jacinto, Facchinetti et al. 2006; Yang, Inoki et al. 2006), the 
regulatory protein Protor, (Pearce, Huang et al. 2007), the inhibitory protein Deptor 
(Peterson, Laplante et al. 2009), and XPLN, an mTORC2-specific inhibitor (Khanna, 
Fang et al. 2013). mTORC2 is involved in actin cytoskeleton organization and cell 
survival by regulating members of the AGC kinase family such as AKT, SGK1 and PKC 
(Jacinto and Lorberg 2008; Alessi, Pearce et al. 2009). Contrary to mTORC1, mTORC2 
is considered rapamycin insensitive. However, in some cell and tissue types prolonged 
treatment of cells with rapamycin induces the dissociation of mTORC2 and de-
phosphorylation of its downstream targets (Sarbassov, Ali et al. 2006). 
 
I.4. mTOR signaling network 
Many regulators of mTOR signaling have been reported. There are many negative 
and positive feedbacks between several of the regulatory proteins, highlighting the 
complexity of the network. Here I highlight the key regulators of this network (Fig. I. 5). 
TSC1/2: A key regulator of mTORC1 signaling is the TSC complex, which is a 
heterodimer composed of hamartin and tuberin, the products of tumor suppressor genes 
TSC1 and TSC2, respectively. When mutated, they are responsible for the tuberous 
sclerosis complex disease, which is characterized by development of hamartoma in a 
variety of organs (Gomez 1991). The TSC complex regulates mTORC1 signaling by 
working as a GTPase activating protein (GAP) for the small Rheb GTPase (Tee, Manning 
et al. 2003). Rheb binds and activates mTORC1 signaling by a mechanism not 
completely understood (Long, Lin et al. 2005; Avruch, Long et al. 2009). 
  FKBP38: A member of the FKBP (FK506 binding protein) family. Members of 
this family function as chaperones by facilitating protein folding (Somarelli, Lee et al. 
2008). FKBP38 was found to be important in size regulation by the TSC complex 
(Rosner, Hofer et al. 2003). Consistent with this function, FKBP38 was found to 
negatively regulate mTORC1 signaling (Bai, Ma et al. 2007). FKBP38 binds to mTOR in 
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a region including the FRB domain where phosphatidic acid and the FKBP12-Rapamycin 
complex bind (Bai, Ma et al. 2007).  
Phosphatidic acid (PA) and Phospholipase D (PLD): Our lab identified the lipid 
second messenger phosphatidic acid, and subsequently phospholipase D1 enzyme, which 
produces PA, as critical mediators of mTOR signaling (Fang, Vilella-Bach et al. 2001; 
Fang, Park et al. 2003; Sun, Fang et al. 2008). Additional reports indicate that both 
mammalian PLD isoforms (PLD1 and PLD2) are involved in mTOR signaling (Ha, Kim 
et al. 2006; Toschi, Lee et al. 2009). The enzymatic activity of PLD1 and PLD2 increases 
upon mitogenic and oncogenic signals (Foster 2009). The identification of the mTOR-
PLD connection provides a mechanistic explanation for the mitogenic and oncogenic 
activities of PLD. PA binds to the FRB domain of mTOR and this interaction is specific 
for PA, as other lipids did not show any affinity for this domain (Fang, Vilella-Bach et al. 
2001). A key residue for this interaction is Arg 2109 (Fang, Vilella-Bach et al. 2001), 
which has now been shown to interact directly with the phosphate group of PA (Veverka, 
Crabbe et al. 2008). Therefore, an increasing body of evidence supports a critical role of 
PA and PLD enzymes in the regulation of mTOR signaling. However, how PA activates 
mTOR remains incompletely understood. Direct activation of mTORC1 kinase by PA has 
been discovered by our lab (Yoon, Sun et al. 2011). My thesis work in Chapter II 
describes a novel mechanism of PA activation of mTORC1. 
 
I.5. Single-molecule microscopy 
Our knowledge of mTOR complexes is largely derived from conventional 
biochemical approaches. However, these approaches suffer from limitations that may 
hinder the complete understanding of protein complexes. To fully decipher the 
complicated processes of mTOR complex formation and signaling, my thesis work 
delved into single-molecule approaches. 
Before the 1980’s, it was not possible to observe single molecule dynamics in real 
time. Spectroscopy and experiments performed at low temperatures proved it was 
possible to detect single molecules (Moerner and Kador 1989). This allowed the direct 
observation of new molecular behaviors, heterogeneity, and dynamics over time. With 
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additional technological advancements, it is now possible to investigate the behavior of 
single molecules in real-time at room temperature. 
The imaging of individual biomolecules has had a tremendous impact on 
biomedical research.  We can study the fluctuations of different enzymatic states, 
biological processes in live cells, membrane behaviors, and structural analysis (Sako and 
Yanagida 2003). Importantly, studying individual molecules allows direct observation of 
the behavior of each molecule rather than an average behavior of many molecules. 
To observe individual molecules in single-molecule microscopy, the molecules 
must first be present at a very low concentration. If attached to a surface, molecule 
density should be in the range of 0.2 molecules/μm2. This surface density ensures that 
each molecule is sufficiently apart from each other allowing the optical detection of each 
individual molecule. Molecules are then visualized using total internal reflection 
fluorescent (TIRF) microscopy.  TIRF microscopy is based on the creation of an 
evanescent wave generated by a beam of light entering between two optical media (glass 
and oil) in a critical angle. The evanescent wave penetrates the sample to a depth of 
approximately 100 nm. This allows the molecules that are very closed to the surface to be 
excited by the evanescent wave. The emitted signal is usually recorded by a high-
sensitivity camera that allows the recording of hundreds of individual molecules with 
millisecond-time resolution. 
 
I.6. Single-molecule pulldown (SiMPull) 
Most proteins in the cell do not work alone.  Instead, they are found in protein 
complexes. These complexes are regulated in many ways, but one of the most important 
mechanisms is by interacting with other cellular proteins. Traditional biochemical 
methods to study protein-protein interactions have been instrumental in our current 
understanding of signaling networks. The most common way to detect protein-protein 
interactions is by performing a pulldown assay. In this assay, a protein of interest (bait) 
will bring along its binding partners (prey). These binding partners are then identified 
using Western blotting or mass spectrometry.  
However, this ensemble assay presents several limitations: 1) Most detected 
interacting partners must be tightly associated in order to survive the cell lysis and 
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stringent washing conditions used to remove non-specific binding proteins. 2) After the 
pulldown assay is completed, interacting proteins are detected via western blotting. This 
presents a concern since proteins must be separated by size during gel electrophoresis and 
then transferred to a membrane for subsequent blotting with primary and secondary 
antibodies. This leads to the detecting of fewer molecules than the true number in the 
complex, and thus loss of sensitivity. 3) Because many steps are involved, conventional 
pull-down assays take several hours, making them cumbersome as well as non-
physiological.  4) It is not possible to determine the stoichiometry of a particular protein 
in a complex, and it cannot be revealed the physiological permutations of these protein-
protein interactions. Therefore, deeper understanding of the complexity of protein-protein 
interacting networks will require molecular dissection beyond the current state of 
traditional biochemical assays. 
Recently, a new approach was developed that addresses these limitations. This 
new assay, named single-molecule pulldown (SiMPull) and developed by our 
collaborator Prof. Taekjip Ha’s laboratory, combines the principles of conventional 
pulldown assay and the power of single-molecule fluorescent microscopy (Jain, Liu et al. 
2011). In SiMPull, protein complexes are pulled down from freshly lysed cells directly 
onto quartz slides prepared for single-molecule fluorescence microscopy (Fig. I. 6). 
SiMPull presents several advantages over conventional pulldown assays: 1) It enables 
direct visualization of individual cellular protein complexes. 2) It has the potential to 
differentiate between multiple subcomplexes and configurations. 3) When proteins are 
stoichiometrically labeled, for example, using fluorescent protein tags such as YFP, 
SiMPull can reveal the stoichiometry of the protein complexes via single-molecule 
fluorescence photobleaching step analysis. 3) The whole assay can be completed in a 
short time, 1-30 minutes. 4) SiMPull can serve as a preparatory tool, in which functional 
macromolecules can be pulled-down directly from cell extracts for subsequent single-
molecule biochemistry in situ.  In Chapter III, I will describe the application of SiMPull 
to determine the stoichiometry and assembly of mTORC1 and mTORC2 in freshly 
prepared cell lysates, as well as the effects of nutrients, growth factors, and the drug 
rapamycin on these complexes.  
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I.7. Lipid-protein interactions  
Signaling lipids, such as phospholipids, regulate a myriad of cellular processes. For 
example, Phosphatidylinositol 3-phosphate (PI(3)P) is a key regulator of membrane 
trafficking, autophagy, and cell growth (Burman and Ktistakis 2010; Yoon, Du et al. 
2011). Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) is involved in vesicle fusion, 
membrane trafficking, and actin cytoskeletal assembly (Di Paolo and De Camilli 2006). 
Phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3) regulates cell growth, proliferation, 
survival and metabolism. Consistent with this, PIP3 is involved in diseases such as 
diabetes and cancer (Cantley 2002). Phosphatidic acid (PA) regulates cell growth and 
proliferation via mTORC1 and membrane trafficking (Jenkins and Frohman 2005; Sun 
and Chen 2008).  
Lipid-protein interactions play critical roles in the assembly of signaling complexes. 
However, the mechanisms that regulate such interactions are not well understood. 
Signaling lipids can bind to specific proteins and recruit them to membranes in different 
cellular compartments, or regulate the assembly with other cellular proteins. Additionally, 
lipids can induce activation or inhibition of enzymes by allosteric effects.  
The majority of the biophysical methods used to measure lipid-protein interactions 
are performed with purified proteins. Examples of these methods include surface-
plasmon resonance, isothermal titration calorimeter, and size-based methods using 
chromatography or centrifugation.  To date, only a handful of studies have probed these 
interactions with single-molecule resolution (Scott, Musselman et al. 2012).  A major 
limitation of these studies lies in using purified recombinant proteins, which may not 
recapitulate function in vivo. Additionally, these assays are not performed in equilibrium 
since the unbound protein or lipids are separated from the lipid-protein complex before 
final detection. Finally, transient lipid-protein interactions cannot be detected by these 
methods due to non-equilibrium conditions and low detection sensitivity. In Chapter IV 
of my thesis, I describe the development of a new assay to probe lipid-protein 
interactions with single-molecule resolution in real-time with whole cell lysates. 
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I. 8. Figures 
 
 
 
Figure I. 1. Upstream and dowmstream of mTOR. The Schematic shows different 
stimuli, such as nutrients, growth factors, energy levels, and stress inducers that transmit 
signals to mTOR. mTOR integrates these signals to regulate biological processes such as 
cell growth, proliferation, differentiation, and metabolism.   
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Figure I. 2. mTOR signaling in disease. The schematic shows human diseases where 
mTOR signaling is involved. Although mTOR itself is not genetically mutated in 
diseases, key upstream regulators of mTOR signaling are mutated in genetic diseases. 
mTOR is also involved in cancer, diabetes and obesity, and aging. 
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Figure I. 3. Domain composition of PIKK-family members. The schematic shows the 
domains present in all members of the PIKK family. mTOR has an additional domain 
named FRB (Fkbp12-rapamycin binding domain), which is not present in other PIKK-
family members. 
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Figure I. 4. mTOR complexes. The diagram shows the subunit compositions of 
mTORC1 and mTORC2. Each complex has unique components (Raptor-PRAS40 in 
mTORC1 and Rictor-mSin in mTORC2) and shared components (mTOR, mLST8, 
Deptor). These subunit compositions allow substrate selectivity and participation of the 
two complexes in different biological processes. 
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Figure I. 5. Key regulators of mTOR signaling. TSC1/2 is an upstream regulator of 
mTORC1. TSV1/2 has GAP (GTPase activating protein) activity toward the small G 
protein Rheb. PLD1 produces PA and synergizes with Rheb to activate mTORC1. 
FKBP38 is an inhibitor of mTORC1 that binds to a region including the FRB (FKBP12-
rapamycin binding domain). Activated mTORC1 phosphorylates  the substrates S6K1 
and 4EBP1. 
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FKBP38 Raptor
mTOR
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Figure I. 6. Single molecule pulldown (SIMPull).  Quartz slides are functionalized with 
PEG and doped with PEG-biotin. Biotinylated antibodies against a protein of interest are 
immobilized using NeutrAvidin. When a cell extract is added to the chamber, the 
antibody captures the protein of interest together with its associating proteins. When the 
protein is fluorescently tagged, it can be directly visualized using a single-molecule 
fluorescent microscope.  
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CHAPTER II 
Phosphatidic acid activates mammalian target of rapamycin complex 1 
(mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and 
exerting an allosteric effect1 
 
II. 1. Introduction 
 The mammalian target of rapamycin (mTOR) assembles a signaling network that 
regulates a myriad of cellular and developmental processes and has emerged as a 
promising therapeutic target in various diseases including cancer (Martin and Hall 
2005; Sarbassov, Ali et al. 2005; Guertin and Sabatini 2007). As a protein Ser/Thr 
kinase, mTOR exists in two biochemically and functionally distinct complexes – 
mTORC1 and mTORC2 – that mediate rapamycin-sensitive and rapamycin-
insensitive signaling, respectively. The two complexes are defined by the presence of 
raptor in mTORC1 and rictor in mTORC2, although they also contain other 
components (Sarbassov, Ali et al. 2005). The best characterized substrates of 
mTORC1 kinase are ribosomal S6 kinase 1 (S6K1, phosphorylation at Thr389) and 
eukaryotic initiation factor 4E binding protein 1 (4E-BP1, phosphorylation at 
Thr37/46), both regulators of protein synthesis and both critically involved in mTOR 
regulation of cell growth and proliferation (Fingar and Blenis 2004; Ma and Blenis 
2009). mTORC2 phosphorylates Akt at the hydrophobic motif (Ser473), which is 
required for Akt activation. In addition, mTORC2 phosphorylates Akt and cPKC at 
their turn motif, which stabilizes the kinases (Facchinetti, Ouyang et al. 2008; 
Ikenoue, Inoki et al. 2008). 
Two major types of upstream signals impinge on the mTORC1 pathway in cell 
growth: mitogens and amino acids. The Rag small G proteins, and separately, the 
class III phosphatidylinositol 3-kinase hVps34, mediate amino acid signaling to 
mTORC1 (Avruch, Long et al. 2009). The tuberous sclerosis complex TSC1/TSC2 
receives mitogenic signals, among other signals, upstream of mTORC1 (Li, 
                                                
1This chapter appeared in its entirety in The Journal of Biological Chemistry 286 (2011), pages 29568-
74 by MeeSup Yoon*, Yuting Sun*, Edwin Arauz*, Yu Jiang and Jie Chen. (*Co-first authors) 
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Corradetti et al. 2004). The target of TSC’s GTPase activating protein (GAP) activity 
is the small G protein Rheb, which activates mTORC1 signaling (Manning and 
Cantley 2003). Several mechanisms have been proposed for Rheb activation of 
mTORC1: (a) direct binding of Rheb to mTOR stimulates the kinase activity of 
mTORC1 (Long, Lin et al. 2005); (b) as an effector for Rheb, phospholipase D (PLD) 
mediates Rheb activation of mTORC1 (Sun, Fang et al. 2008); (c) Rheb displaces 
FKBP38, an inhibitor of mTORC1 kinase, and consequently activates mTORC1 (Bai, 
Ma et al. 2007). 
Work from our laboratory, and subsequently many others, has established the 
lipid second messenger phosphatidic acid (PA) as a key mediator of mitogenic 
activation of mTORC1 (Fang, Vilella-Bach et al. 2001; Foster 2007; Sun and Chen 
2008). Phospholipase D (PLD), an enzyme that converts phosphatidylcholine (PC) to 
PA (Frohman, Sung et al. 1999), is a critical component upstream of the mTORC1 
pathway in the regulation of cell growth (Fang, Park et al. 2003; Foster 2007; Sun and 
Chen 2008). PA, with remarkable specificity, interacts with the FKBP12-rapamycin 
binding domain (FRB) of mTOR located N-terminal to the kinase domain, in 
competition with FKBP12-rapamycin binding (Fang, Vilella-Bach et al. 2001). 
Recently, a solution structure of the FRB-PA complex (Veverka, Crabbe et al. 2008) 
has validated the biochemically derived knowledge of FRB-PA interaction. 
 As a signaling lipid, PA has been found to have many effectors (Stace and 
Ktistakis 2006). Membrane translocation of the protein upon binding to PA is a major 
mechanism by which PA regulates its effectors, but PA is also believed to 
allosterically regulate the enzymatic activities of some of its effectors (Stace and 
Ktistakis 2006). The exact mechanism or a common mode for the allosteric effect of 
PA has not emerged, partly due to the lack of any well-defined PA-binding module in 
PA effectors. Although it is well established that PA activates mTORC1 signaling in 
cells, the mechanism behind this activation has remained a long-standing puzzle. 
There is no evidence for PA induction of mTOR membrane translocation, and our 
earlier experimental evidence also argued against the possibility of PA activating 
mTOR catalytic activity (Fang, Vilella-Bach et al. 2001; Chen and Fang 2002). 
However, recent advances in the understanding of the biochemistry and signaling of 
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mTOR have prompted us to reconsider the role of PA in the context of mTOR kinase 
activity. Here we report that PA directly activates mTORC1 kinase through a dual 
mechanism – displacement of the endogenous inhibitor FKBP38 from mTOR and 
allosteric activation of the kinase. 
 
II. 2. Materials and methods 
II. 2. 1. Reagents 
 The antibodies used in this study were obtained from the following commercial 
sources: Flag M2, Sigma; HA (16B12) and Myc (9E10.2), Covance; FKBP38, R&D 
Systems; GST and His, Santa Cruz; tubulin, Abcam; raptor and rictor, Bethyl 
laboratory, Inc.; all other antibodies, Cell Signaling. C8-PA, 1-palmitoyl-2-oleoyl-PA 
and -PC were from Avanti Lipids. Glutathione beads were from GE Healthcare. 
Protein G-agarose and His-Akt were from Millipore. All other reagents were from 
Sigma. 
 
II. 2. 2. Plasmids 
 GST-S6K1 (a.a.332-421) was constructed by inserting the corresponding S6K1 
cDNA into pGEX-2T (GE Healthcare). Raptor shRNA constructs were obtained from 
Addgene (Kim, Sarbassov et al. 2002). The following plasmids were previously 
described: Myc-S6K1 (Fang, Vilella-Bach et al. 2001); Flag-4EBP1 (Kim and Chen 
2000); Flag-mTOR (Vilella-Bach, Nuzzi et al. 1999); HA-FKBP38, GST-FKBP38, 
and GST-mTOR-225 (Bai, Ma et al. 2007). 
 
II. 2. 3. Cell culture 
 Human embryonic kidney (HEK) 293 cells were grown in DMEM containing 
10% fetal bovine serum (FBS) at 37 °C with 5% CO2. Transient transfections were 
performed with PolyFect (Qiagen) or Lipofectamine (Invitrogen) following 
manufacturers’ recommendations and as previously described (Sun, Fang et al. 2008). 
C8-PA stimulation of the cells was as described previously (Sun, Fang et al. 2008). 
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II. 2. 4. Lentivirus-mediated RNAi 
 All shRNAs were obtained from Sigma-Aldrich in the pLKO.1-puro vector 
(MISSION® shRNA). Lentivirus packaging and testing were performed as previously 
described (Yoon and Chen 2008). HEK293 cells were infected with the lentiviruses in 
growth medium containing 6 μg/ml polybrene, followed by selection in 1.5 μg/ml 
puromycin for 3-4 days. The scramble and PLD1 TRC shRNA clones were 
previously described (Sun, Fang et al. 2008). Human FKBP38 shRNA was 
TRCN0000010595. 
 
II. 2. 5. Protein purification 
 GST-fusion proteins (GST-mTOR-225, GST-FKBP38, GST-FKBP12) were 
expressed in E. coli, purified using glutathione beads, and cleaved of the GST tag as 
previously described (Fang, Vilella-Bach et al. 2001; Bai, Ma et al. 2007). 
 
II. 2. 6. In vitro binding assays 
 Purified GST-FKBP38 and mTOR-225 proteins were mixed at 5 μg each and 
incubated on ice in 500 μl binding buffer (40 mM Tris-Cl, pH7.5, 150 mM NaCl, 2 
mM EDTA, 2 mM EGTA, 1 mM DTT) for 15 min. Where applicable, lipid vesicles 
were pre-incubated with mTOR-225 for 15 min prior to addition of GST-FKBP38. 
PA vesicles (50% PA + 50% PC) and PC vesicles (100% PC) were made by probe-
sonication as previously described (Fang, Vilella-Bach et al. 2001). Glutathione beads 
were used to pull down GST fusion proteins, and the beads were washed with binding 
buffer, followed by boiling in SDS samples buffer and Western analysis. 
 
II. 2. 7. Cell lysis, immunoprecipitation, and western analysis 
Cells were rinsed once with ice-cold PBS and lysed in ice-cold lysis buffer (40 
mM HEPES, pH7.2, 120 mM NaCl, 10 mM pyrophosphate, 50 mM NaF, 10 mM b-
glycerophosphate, 2 mM EDTA, 1x Sigma protease inhibitor cocktail, and 0.3% 
CHAPS). The supernatant after microcentrifugation at 13,000 rpm for 10 min was 
collected and subjected to immunoprecipitation at 4℃ with various antibodies in the 
lysis buffer. The beads were washed 3 times with lysis buffer, and then boiled in SDS 
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sample buffer for 5 min. Proteins were resolved on SDS-PAGE and transferred onto 
PVDF membrane (Millipore), followed by incubation with various antibodies 
according to the manufacturers’ recommendations. Detection of horseradish 
peroxidase-conjugated secondary antibodies was performed with Western 
LightningTM Chemiluminescence Reagent Plus (Perkin Elmer, Inc.). Quantification of 
Western band intensities was performed by densitometry of X-ray film images using 
the software Image J. 
 
II. 2. 8. In vitro mTOR kinase assays 
 mTORC1 and mTORC2 were immunoprecipitated using anti-raptor and anti-
rictor antibodies, respectively, followed by incubation with protein G agarose beads. 
The kinase assays were performed following procedures described by Ikenoue et al. 
(Ikenoue, Hong et al. 2009). mTORC1 kinase assays were carried out at 30 ℃ for 30 
min in 25mM HEPES (pH 7.4), 50 mM KCl, 10 mM MgCl2 and 250 µM ATP, with 
100 ng GST-S6K1 as the substrate. mTORC2 kinase assays were carried out at 37 ℃ 
for 30 min in 25mM HEPES (pH 7.4), 100 mM potassium acetate, 1 mM MgCl2 and 
500 µM ATP, with 250 ng His-Akt as the substrate. Where applicable, PA or PC 
vesicles, and/or FKBP38 were added to the immunocomplexes 15 min before 
initiation of the kinase assay by the addition of ATP. Reactions were stopped by the 
addition of 20 μl SDS sample buffer and boiling. 
 
II. 3. Results 
II. 3. 1. PA stimulates mTORC1 kinase activity 
 To evaluate a potential effect of PA on the kinase activity of mTOR in cells, we 
examined the phosphorylation of mTOR on Ser2481, an autophosphorylation site that 
has recently been reported to monitor mTORC-specific catalytic activities (Soliman, 
Acosta-Jaquez et al. 2009). To avoid potential complications from exogenous PA-
derived lysophosphatidic acid (LPA) (Billon-Denis, Tanfin et al. 2008), which would 
initiate signaling through the membrane-bound LPA receptors, we used a short-chain 
PA (C8-PA) for delivery into cells, which would not be converted into active LPA 
(van Corven, van Rijswijk et al. 1992; Fischer, Nusser et al. 2001). mTORC1 and 
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mTORC2 were isolated from HEK293 cells by immunoprecipitation of raptor and 
rictor, respectively. As shown in Figure II. 1A, C8-PA treatment of the cells in the 
absence of any mitogen induced Ser2481 phosphorylation of raptor-associated 
mTOR; rictor-associated mTOR, on the other hand, displayed a higher basal level of 
pSer2481 that was not affected by PA stimulation. PA activation of mTORC1 
signaling was confirmed by S6K1 phosphorylation on Thr389, whereas phospho-
Ser473-Akt, an indicator of mTORC2 signaling, was not detectable upon PA 
treatment (Fig. II. 1B). These results suggest that PA activates mTORC1, but not 
mTORC2, kinase activity in cells.  
 Next, we asked whether PA could directly activate mTORC1 kinase in vitro. 
Previously we had found the FRB domain of mTOR to bind specifically to PA-
containing vesicle in vitro, and not vesicles of other lipid compositions including PC, 
phosphatidylethanol, phosphatidylserine and various phosphatidylinositides (Fang, 
Vilella-Bach et al. 2001). Kinase assays were performed with immunoprecipitated 
endogenous mTORC1 and bacterially purified GST-S6K1 as a substrate. Vesicles 
containing 50% 1-palmitoyl-2-oleoyl-PA (PA) and 50% 1-palmitoyl-2-oleoyl-
phosphatidylcholine (PC) were added to the kinase reaction, with 100% PC vesicles 
as a negative control. As shown in Figure II. 2A, PA stimulated the in vitro kinase 
activity of mTORC1 while PC had no effect. Most likely owing to a narrow dynamic 
range of the in vitro assay, the effects of PA vesicles were similar at 100 µM and 200 
µM (Fig. II. 2A), and mild at 20-50 µM (data not shown). The kinase activity of 
mTORC2, assayed with Akt as a substrate, was unaffected by PA vesicles at the same 
concentrations (Fig. II. 2B). The degrees of S6K1 and Akt phosphorylation were 
measured by densitometry to quantify the kinase activities (Fig. II. 2A and B, lower 
panels). These data demonstrate that PA selectively activates mTORC1 kinase in 
vitro. 
 
II. 3. 2. PA disrupts FKBP38-mTOR interaction 
 To probe into the mechanism by which PA activates mTORC1 kinase, we 
considered the role of FKBP38 as an endogenous inhibitor of mTORC1 (Bai, Ma et 
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al. 2007). Because FKBP38 binds mTOR through a region that overlaps with the PA-
binding FRB domain (Fang, Vilella-Bach et al. 2001; Bai, Ma et al. 2007), it 
appeared plausible that PA could compete with FKBP38 for mTOR binding as a 
mechanism of activating mTORC1. However, although several groups independently 
demonstrated a role of FKBP38 as a negative regulator of mTORC1 (Bai, Ma et al. 
2007; Dunlop, Dodd et al. 2009; Peng, Liang et al. 2010), others challenged this 
conclusion (Maehama, Tanaka et al. 2008; Wang, Fonseca et al. 2008). Therefore, we 
deemed it necessary to re-examine the role of FKBP38 in mTORC1 signaling in the 
Chen laboratory. We found that overexpression of FKBP38 in HEK293 cells 
inhibited serum-stimulated phosphorylation of both S6K1 and 4EBP1 (Fig. II. 3A), 
whereas knockdown of endogenous FKBP38 enhanced the phosphorylation of those 
mTORC1 targets (Fig. II. 3B).  
 To test the hypothesis that PA competes with FKBP38 for mTOR binding, we 
first performed in vitro binding assays with bacterially expressed and purified mTOR 
fragment (a.a. 1967-2191; designated mTOR-225) and GST-FKBP38. The specific 
interaction between mTOR-225 and FKBP38 (Bai, Ma et al. 2007) was confirmed by 
GST pull-down assays (Fig. II. 4A). Importantly, pre-incubation with PA vesicles, but 
not PC vesicles, disrupted the interaction between GST-FKBP38 and mTOR-225 in a 
dose-dependent manner (Fig. II. 4B). Thus, a competition between PA and FKBP38 
for binding to the mTOR fragment is evident in vitro. It is not feasible to mimic 
physiological concentrations in the in vitro vesicle binding assays, as local 
concentrations of PA in a cell are not known (but could conceivably be very high).  
 We also confirmed the interaction between FKBP38 and full-length mTOR by co-
IP of epitope-tagged FKBP38 and mTOR (Fig. II. 4C), the latter expressed at a level 
comparable to endogenous mTOR (data not shown). Moreover, the FKBP38-mTOR 
interaction was disrupted when cells were exposed to C8-PA (Fig. II. 4C). PLD1 is 
responsible for the production of PA upstream of mTORC1 (Fang, Park et al. 2003; 
Sun and Chen 2008). When PLD1 was knocked down, accompanied by diminished 
S6K1 phosphorylation as expected, an increased amount of mTOR was associated 
with FKBP38 (Fig. II. 4D). Collectively, these observations strongly suggest that the 
FKBP38-mTOR interaction is disrupted by PLD1 signaling and PA. 
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II. 3. 3. PA antagonizes the inhibitory effect of FKBP38 on mTORC1 kinase 
activity and signaling 
 Next we asked whether the PA/FKBP38 competition for mTOR binding would 
manifest into an antagonistic relationship on the regulation of mTORC1 kinase 
activity. Purified FKBP38 inhibited the in vitro kinase activity of mTORC1 in a dose-
dependent manner (Fig. II. 5A), consistent with previous reports (Bai, Ma et al. 2007; 
Dunlop, Dodd et al. 2009). FKBP12 added at the same concentrations did not have 
any effect (Fig. II. 5A), confirming the specificity of FKBP38 inhibition of mTORC1. 
Significantly, the presence of PA vesicles, but not PC vesicles, in the reaction rescued 
kinase activity from FKBP38 inhibition (Fig. II. 5B), suggesting that PA directly 
antagonizes the inhibitory effect of FKBP38 in vitro. 
 We also examined the relationship between PA and FKBP38 in the context of 
mTORC1 signaling in cells. As shown in Figure II. 6A, C8-PA stimulation of S6K1 
phosphorylation in the absence of any mitogen was inhibited by FKBP38 
overexpression. On the other hand, inhibition of serum-activation of S6K1 by 
overexpressed FKBP38 was reversed by exogenous PA (Fig. II. 6B). We did not 
observe a reversal of FKBP38 inhibition of mTORC1 signaling with increasing C8-
PA concentrations in the absence of any other mitogen (data not shown), possibly due 
to limited delivery efficiency of exogenous PA. It is also not feasible to estimate or 
mimic physiological concentrations of PA, as endogenous PA may be highly 
localized. Nevertheless, our data taken together are fully consistent with the model 
that PA activates mTORC1 by antagonizing FKBP38 both in vitro and in cells.  
 
II. 3. 4. PA is also an allosteric activator of mTORC1 kinase 
 If removing FKBP38 were the sole mechanism for PA activation of mTORC1, 
one would expect that, in the absence of FKBP38, PA would not further stimulate 
mTORC1. To probe into this issue, we knocked down FKBP38. As shown in Figure 
II. 7A, the level of endogenous FKBP38 was drastically reduced by lentivirus-
delivered shRNA, which was accompanied by modestly increased S6K1 and 4EBP1 
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phosphorylation in serum-starved cells. Interestingly, exogenous C8-PA further 
stimulated mTORC1 signaling despite the FKBP38 knockdown (Fig. II. 7A). The 
dramatic degree of stimulation is unlikely to be explained by any residual FKBP38 
protein after knockdown. Rather, this data strongly suggests that displacement of 
FKBP38 alone is insufficient for PA activation of mTORC1 signaling. Nevertheless, 
this does not contradict the necessity of FKBP38 displacement by PA for the 
activation. 
 To assess the role of endogenous PA, we knocked down PLD1. If the 
predominant role of PA were to remove FKBP38, we would expect that, in the 
absence of FKBP38, PLD1 would no longer be essential for mTORC1 signaling. 
However, we found that PLD1 knockdown abolished the ability of FKBP38 
knockdown to induce mTORC1 signaling (Fig. II. 7B, compare lane 2 and lane 4). 
This is consistent with the observation in Figure II. 7A, suggesting that PA is required 
for mTORC1 activation in addition to removing FKBP38. PLD1 knockdown alone 
did not have an obvious effect on the basal activity of mTORC1 (Fig. II. 7B), as 
expected (Fang, Park et al. 2003). It was noted that FKBP38 knockdown was less 
efficient, and the effect on mTORC1 signaling less pronounced, when the cells were 
transduced by both FKBP38 and PLD1 shRNA lentiviruses (compare Fig. II. 7A and 
Fig. II. 7B), likely because selection of cells infected by two types of viruses relied on 
the same drug (puromycin). Nevertheless, this FKBP38 reduction led to reproducible 
mTORC1 activation that was eliminated by PLD1 knockdown, as clearly shown by 
the quantitative measurements of S6K1 and 4E-BP1 phosphorylation (Fig. II. 7C). 
 To further validate the observations above, we carried out in vitro kinase assays 
with mTORC1 isolated from FKBP38 knockdown cells. As shown in Figure II. 7D, 
PA vesicles stimulated the kinase activity of FKBP38-deficient mTORC1, supporting 
the notion that PA has a positive role in the absence of FKBP38. Of note, the 
immunoprecipitated mTORC1 activity was indistinguishable between FKBP38 
knockdown and control cells both in the presence and absence of added PA vesicles 
(Fig. II. 7D), suggesting that even without knockdown the amount of FKBP38 
associated with the mTORC1 complex under our experimental conditions was most 
likely negligible. 
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 Therefore, in addition to displacing FKBP38, PA also activates mTORC1 through 
another mechanism. The other known inhibitors of mTORC1 are PRAS40 and 
DEPTOR, both of which would be absent in the mTORC1 immunoprecipitate here as 
it was subjected to high salt (500 mM NaCl) wash that removed these two proteins 
((Sancak, Thoreen et al. 2007; Peterson, Laplante et al. 2009) and data not shown). 
The in vitro assay system also made it virtually impossible for PA to recruit an 
activator. Hence, collectively the current observations point to the simplest model that 
the physical interaction between PA and mTOR exerts an allosteric effect that is 
required for the kinase activity of mTORC1 after displacement of FKBP38, although 
the involvement of a third factor (an unknown inhibitor) cannot be formally excluded. 
 
II. 4. Discussion 
Our studies have revealed direct activation of the mTORC1 kinase by 
phosphatidic acid and identified a dual mechanism by which PA activates mTORC1: 
displacing FKBP38 and exerting an allosteric effect on the catalytic activity (Fig. II. 
8). These findings provide answers to the long-standing question of how PA activates 
mTOR signaling. The new mechanistic insights may facilitate the exploration of the 
tremendous therapeutic potential of this signaling network. 
 It is noteworthy that we had previously failed to observe an effect of PA on 
mTOR catalytic activity (Fang, Vilella-Bach et al. 2001; Chen and Fang 2002). One 
plausible explanation for the discrepancy may come from the conditions of isolating 
mTOR for in vitro kinase assays. In previous studies we had used Triton X-100 as the 
detergent in cell lysis prior to mTOR immunoprecipitation, whereas in the current 
study CHAPS was used and mTORC1 was isolated by raptor pull-down. As reported 
by Kim et al. (Kim, Sarbassov et al. 2002), the raptor-mTOR interaction would be 
disrupted by Triton. The loss of raptor may have prevented PA activation of 
mTORC1. 
 We had previously reported a mutation in mTOR (R2109A) that had dampened 
FRB binding to PA in vitro and mTOR signaling in cells by ~50% (Fang, Vilella-
Bach et al. 2001). This mTOR mutant, however, did not display differential 
sensitivity to PA compared to wt mTOR in FKBP38 binding (data not shown). It is 
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possible that limitations in the vesicle binding assay and cellular delivery of C8-PA 
render insufficient dynamic ranges to discern the partial defect of the R2109A 
mutant. With the solution structure of the FRB-PA complex (Veverka, Crabbe et al. 
2008) as a guide, identification of additional mutations in FRB that drastically disrupt 
the PA-FRB interaction may be possible. Such mutants would be desirable for future 
investigations of PA in the regulation of mTORC1. 
 Although our present data suggest that PA selectively activates mTORC1 and not 
mTORC2 (Figs. 1 and 2), it has been proposed by Foster and colleagues (Toschi, Lee 
et al. 2009) that PA is required for the assembly of both mTORC1 and mTORC2. 
These two conclusions need not be mutually exclusive. In the present studies, we 
examined PA for its acute effect in stimulating cells and in directly activating mTOR 
kinase. On the other hand, the effects that Toschi et al. (Toschi, Lee et al. 2009) have 
observed may stem from a basal level of PA in maintaining the integrity of mTOR 
complexes prior to activation of the kinases. It will be interesting in future 
investigations to determine whether the activation of mTORC1 and assembly of 
mTOR complexes share the same mode of PA-mTOR interaction or represent two 
molecularly distinct mechanisms of PA action. 
 The recent controversy surrounding FKBP38’s role in regulating mTORC1 
prompted us to re-examine this reported endogenous inhibitor, and our results 
described here clearly support the model that FKBP38 binds and inhibits mTORC1. 
We and others (Dunlop, Dodd et al. 2009) observed that recombinant FKBP38 
inhibited mTORC1 signaling in cells only when it was highly overexpressed, which 
may explain the absence of FKBP38 effect in similar experiments performed by some 
groups (Maehama, Tanaka et al. 2008; Wang, Fonseca et al. 2008). The requirement 
of high levels of recombinant FKBP38 to exert an inhibitory effect on mTORC1 does 
not necessarily mean the FKBP38 mechanism is an inefficient one; one could 
envision that endogenous FKBP38 might be highly localized for its mTORC1-
regulating function and/or that high concentrations of FKBP38 might be necessary to 
set a threshold to ensure signaling fidelity. In vitro, the inhibitory effect of 
recombinant FKBP38 on mTORC1 kinase activity was easily detected (Fig. II. 5A), 
most likely owing to the condition of mTORC1 isolation that led to the dissociation 
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of endogenous FKBP38. The reported ability of Rheb to bind FKBP38 and displace it 
from mTOR (Bai, Ma et al. 2007) has also been disputed (Wang, Fonseca et al. 2008; 
Uhlenbrock, Weiwad et al. 2009). We have not examined the role of Rheb in our 
studies, as our proposed model of PA action is independent of Rheb-FKBP38 
interaction, although it does not exclude the involvement of Rheb. 
 Displacement of FKBP38 appears to be a simple and effective way for PA to 
activate the mTOR kinase, and yet, to the best of our knowledge, this is the first 
example of PA regulating an effector through removing an inhibitor. mTOR also 
joins a small roster of PA effectors, the enzymatic activities of which are 
allosterically regulated by PA binding (Stace and Ktistakis 2006). The only other 
protein kinase that has been reported to be activated by PA through a possible 
allosteric effect is Fer, a tyrosine kinase that regulates actin polymerization in cell 
migration (Itoh, Hasegawa et al. 2009). Other than the fact that PA binds at a site N-
terminal to the kinase domain, mTOR and Fer do not share any common feature in 
their PA binding domains. Since PA stimulates mTORC1 activity on an 
autophosphorylation site but not mTORC2 activity on the same site (Fig. II. 1), the 
allosteric effect of PA is unlikely to simply confer catalytic activation or substrate 
specificity of the kinase domain; other components in mTORC1, raptor in particular, 
most likely play an integral role. Future structural studies will be needed to shed light 
on the exact mode of allosteric regulation by PA of mTOR, or of any other kinase. 
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II. 5. Figures 
 
 
Figure II. 1. PA activates mTORC1 autophosphorylation in cells. (A) HEK293 
cells were serum-starved overnight, and then stimulated with 300 µM C8-PA for 30 
min. mTORC1 and mTORC2 were immunoprecipitated with anti-raptor and anti-
rictor antibodies, respectively, followed by Western blotting. (B) Cells were serum-
starved overnight, and then stimulated with 300 µM C8-PA or 20% serum for 30 min 
followed by cell lysis and Western blotting. (C) Cells were transduced with lentivirus 
expressing raptor shRNA, serum-starved, and then stimulated with 300 µM PA or 
20% serum for 30 min, followed by Western analysis of the cell lysates. Each 
experiment was performed at least 3 times, and the representative blots are shown. 
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Figure II. 2. PA stimulates mTORC1 kinase activity in vitro. (A) Raptor was 
immunoprecipitated from HEK293 cells and subjected to in vitro kinase assays using 
GST-S6K1 as the substrate. PA or PC vesicles were added at 100 µM and 200 µM 
prior to kinase assays in the samples indicated. The pS6K1 and GST-S6K1 blots with 
raptor IP were quantified by densitometry, and the relative ratios of pS6K1 versus 
GST-S6K1 were calculated with control (no vesicles) designated as 1. (B) Rictor was 
immunoprecipitated from HEK293 cells and subjected to in vitro kinase assays using 
His-Akt as the substrate. The pAkt and His-Akt blots were quantified as described in 
(A). The data shown in the graphs are mean ± standard deviation of three independent 
experiments. Each data point is compared to the control by one-sample t test and 
significantly different data points are indicated: *P<0.05, **P<0.01. 
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Figure II. 3. FKBP38 is an endogenous inhibitor of mTORC1 signaling. (A) 
HEK293 cells were transfected with Myc-S6K1 (left panels) or Flag-4EBP1 (right 
panels) with or without HA-FKBP38, serum starved, and then stimulated with 10% 
serum for 30 min, followed by Western analysis of cell lysates. Note that the 
phosphorylation state of 4EBP1 was reflected by band-shift on Flag-4EBP1 blot in 
addition to phospho-specific antibody recognition. (B) Cells were transduced with 
lentivirus expressing FKBP38 shRNA or a hairpin of scrambled sequence as control, 
serum-starved, and then lysed for Western analysis. 
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Figure II. 4. PA disrupts FKBP38-mTOR interaction. (A) GST pull-down assays 
were performed with purified mTOR-225 and GST-FKBP38, with GST as a negative 
control. Western blots are shown. Note that some free GST was present in the GST-
FKBP38 protein preparation. (B) GST-FKBP38 was pre-incubated with varying 
concentrations of PA (+) or PC (-) vesicles prior to addition of purified mTOR-255 
and subsequent pull-down assays. (C) HEK293 cells were co-transfected with HA-
FKBP38 and Flag-mTOR, followed by serum-starvation and stimulation with 300 
µM C8-PA for 30 min. HA-FKBP38 was immunoprecipitated, followed by Western 
analysis. (D) Cells were transduced with lentivirus expressing PLD1 shRNA, and 
then co-transfected with HA-FKBP38 and Flag-mTOR, followed by IP of HA-
FKBP38 and subsequent Western analysis. Each experiment was performed at least 3 
times, and the representative blots are shown. 
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Figure II. 5. PA antagonizes FKBP38 inhibition of mTORC1 kinase activity in 
vitro. mTORC1 was immunoprecipitated with anti-raptor antibody from HEK293 
cells and subjected to in vitro kinase assays using GST-S6K1 as a substrate. (A) 
FKBP38 and FKBP12 were added at increasing amounts as indicated prior to kinase 
assays. (B) PA or PC vesicles at 100 µM were added together with FKBP38 prior to 
kinase assays. Each experiment was performed at least 3 times, and the representative 
Western blots (or Coomassie Blue stain for FKBP38 in A) are shown. 
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Figure II. 6. PA and FKBP38 antagonize each other in the regulation of 
mTORC1 signaling in cells. (A) HEK293 cells were co-transfected with Myc-S6K1 
and HA-FKBP38, serum-starved, and then stimulated with 300 µM C8-PA, followed 
by Western analysis of cell lysates. (B) Cells were transfected and starved as in (A), 
and stimulated with 10% serum with or without C8-PA, followed by Western analysis 
of cell lysates. Each experiment was performed at least 3 times, and the representative 
blots are shown. 
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Figure II. 7. PA activates mTORC1 in the absence of FKBP38. (A) HEK293 cells 
were transduced with lentivirus expressing FKBP38 shRNA, serum-starved, and then 
stimulated with 300 µM C8-PA, followed by Western analysis of lysates. (B) Cells 
were transduced with lentiviruses expressing shRNA for FKBP38, or PLD1, or both, 
followed by serum starvation and then Western analysis. (C) The Western results 
represented by blots in (B) were quantified by densitometry, and the relative ratios of 
pS6K1 versus S6K1 and p4EBP1 versus 4EBP1 were calculated with control (no 
shRNA) designated as 1. (D) mTORC1 was immunoprecipitated by anti-raptor from 
cells expressing FKBP38 shRNA or a hairpin of scrambled sequence as control, and 
subjected to in vitro kinase assays with or without PA or PC vesicles at 100 µM. The 
Western results were quantified by densitometry, and the relative ratios of pS6K1 
versus GST-S6K1 were calculated with control (no vesicles) designated as 1. The 
data shown are mean ± standard deviation or representative blots of three independent 
experiments. Each data point is compared to the control by one-sample t test and 
significantly different data points are indicated: *P<0.05, **P<0.01.  
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Figure II. 8. A proposed model for PA activation of mTORC1. FKBP38 binds and 
inhibits mTORC1. Upon stimulation of PLD1, PA is produced, which binds mTOR at 
FKBP38-binding site and displaces FKBP38. The physical interaction of PA with 
mTOR also allosterically activates the kinase. 
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CHAPTER III 
Stoichiometry and assembly of mTOR complexes revealed by single-molecule 
pulldown1 
 
III. 1. Introduction 
The mammalian target of rapamycin (mTOR) is a master regulator of crucial 
cellular and developmental processes. As a serine/threonine protein kinase belonging to 
the phosphatidylinositol-3-kinase (PI3K)-related kinase family, mTOR integrates the 
sensing of nutrients, growth factors, oxygen, energy, and different types of stress to 
regulate a myriad of biological processes such as cell growth, proliferation, 
differentiation, and metabolism (Laplante and Sabatini 2012). mTOR functions as part of 
at least two biochemically and functionally distinct complexes—mTORC1 and mTORC2 
(Laplante and Sabatini 2009). mTORC1, better characterized of the two complexes, is the 
rapamycin-sensitive complex, composed of the proteins raptor and mLST8, and it is 
regulated by the inhibitory proteins PRAS40 and DEPTOR (Laplante and Sabatini 2009; 
Peterson, Laplante et al. 2009). mTORC1 is activated by nutrients (such as amino acids), 
growth factors, and cellular energy among other stimuli (Laplante and Sabatini 2009; 
Laplante and Sabatini 2012). mTORC2 contains rictor, mLST8, and mSin, as well as the 
negative regulator DEPTOR (Laplante and Sabatini 2009; Peterson, Laplante et al. 2009). 
PI3K-related kinases (PIKKs) such as ataxia telangiectasia mutated (ATM), ATM 
and Rad3-related protein (ATR), and DNA-dependent protein kinase (DNA-PK) are 
known to oligomerize (Bakkenist and Kastan 2003; Ball and Cortez 2005; Spagnolo, 
Rivera-Calzada et al. 2006). Biochemical and genetic analyses have identified self-
association of mTOR and its orthologs in yeast and Drosophila (Wullschleger, Loewith 
et al. 2005; Takahara, Hara et al. 2006; Wang, Rhodes et al. 2006; Zhang, Billington et 
al. 2006). A cryoelectron microscopy (cryo-EM) study revealed that mTORC1 self-
associates into a dimeric structure (Yip, Murata et al. 2010). Oligomerization of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1This chapter appeared in its entirety in Proceedings of the National Academy of Sciences 111 (2014), 
pages 17833-38 by Ankur jain*, Edwin Arauz*, Vasudha Aggarwal, Nikita Ikon, Jie Chen, and Taekjip 
Ha. (*Co-first authors)  	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mTORC1 has been reported to be sensitive to nutrient status based on biochemical 
analyses of recombinant proteins (Takahara, Hara et al. 2006; Kim, Hoffman et al. 2013). 
Consensus is lacking on the oligomeric state of mTORC2, which has been proposed to be 
monomeric, dimeric, or multimeric (Wullschleger, Loewith et al. 2005; Frias, Thoreen et 
al. 2006; Takahara, Hara et al. 2006; Tao, Barker et al. 2010). High-resolution structural 
analysis of mTORC2 has not been possible thus far, likely owing to its large size and 
multiplicity of interaction partners. 
Ensemble biochemical methods have inherent limitations in analyzing 
multicomponent heterogeneous protein assemblies. These methods do not directly reveal 
the stoichiometry of interaction and offer low-resolution estimates of the sizes of protein 
complexes. Additionally, the lengthy procedures often associated with biochemical 
characterization may lead to loss or alteration of physiological protein complexes. We 
recently reported a single-molecule pulldown (SiMPull) technology that combines the 
principles of conventional pulldown assays with single-molecule fluorescence 
microscopy (Jain, Liu et al. 2011). In SiMPull, protein complexes are pulled down from 
freshly lysed cells directly onto chambers for single-molecule fluorescence microscopy. 
When proteins are stoichiometrically labeled for example using fluorescent protein tags, 
SiMPull can reveal the stoichiometry of the protein complexes via single-molecule 
fluorescence photobleaching step analysis (Jain, Liu et al. 2011). 
We have used SiMPull to investigate the oligomeric assembly of mTORCs. Upon 
validating our approach by demonstrating dimeric assembly of mTORC1, we find that 
mTORC2 is also dimeric and contains two molecules of mTOR and rictor per complex. 
Individual mTORC components are predominantly monomeric, but under physiological 
conditions there is no evidence of monomeric interaction between mTOR and raptor or 
rictor. Multicolor imaging of individual complexes revealed that although the two 
complexes are predominantly distinct, small fractions of mTORC1 and mTORC2 
components coexist in the same complex. Physiological perturbations that abrogate 
mTOR signaling had no effect on the stoichiometry of mTOR complexes, indicating that 
inhibition of mTOR signaling can be achieved without requiring disassembly of mTOR 
complexes or changing their oligomeric state. On the other hand, treatment with 
rapamycin led to transient mTOR–raptor complexes containing one mTOR before 
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complete disassembly of the interaction, whereas mTORC2 stoichiometry was 
unaffected. 
 
III. 2. Materials and methods 
III. 2. 1. Antibodies and other reagents 
All antibodies used were obtained from commercial sources as follows: anti-Flag 
and biotinylated anti-Flag M2 from Sigma-Aldrich; anti-Myc (9E10.2) and anti-HA 
(16B12) from Covance or Abcam (ab26228); anti-GFP from Roche and Rockland 
Immunochemicals; anti-DEPTOR from Novus Biologicals; and rictor, raptor, mLST8, 
and mTOR antibodies from Cell Signaling Technology. Raptor and rictor antibodies for 
immunoprecipitation were from Bethyl Laboratories, and mTOR antibody (N-19) for 
immunoprecipitation was from Santa Cruz Biotechnology. All secondary antibodies for 
Western blotting and SiMPull were from Jackson ImunoResearch Labs. Rapamycin was 
from Calbiochem, EZview Red anti-HA beads and anti-Flag M2 beads from Sigma, 
NeutrAvidin from ThermoFisher, dithiobis(succcinimidyl propionate) (DSP) was from 
Pierce, and BSA from New England Biolabs. 
 
III. 2. 2. Plasmids 
Plasmids pRK5–HA–raptor (Addgene plasmid 8513) (Kim, Sarbassov et al. 
2002), pRK5–HA–mLST8 (Addgene plasmid 1865) (2) and pRK5– myc–rictor 
(Addgene plasmid 1860) (Sarbassov, Ali et al. 2004) were obtained from Addgene. 
pCDNA–Flag–mTOR has been described previously (Vilella-Bach, Nuzzi et al. 1999). 
YFP–raptor was constructed by inserting monomeric eYFP (A206K) cDNA into pRK5–
HA–raptor between the HA tag and raptor sequence. YFP–rictor was constructed by 
replacing the raptor cDNA in YFP–raptor with rictor cDNA from pRK5–myc– rictor. 
pCDNA–mSin1–HA was constructed by cutting mSin1.1– HA from pMSCV–mSin1.1–
HA (Addgene plasmid 12582) (Frias, Thoreen et al. 2006) using BglII and EcoRI, and 
inserted into pCDNA3 cut with BamHI and EcoRI. YFP–mTOR was created by inserting 
mTOR cDNA into the peYFP–C1 plasmid (Clontech). YFP–PRAS40 was constructed by 
replacing the raptor cDNA in YFP–raptor with PRAS40 cDNA from pRK5–HA–
PRAS40 (Addgene plasmid 15481) (Vander Haar, Lee et al. 2007). YFP–DEPTOR was 
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constructed by replacing the raptor cDNA in YFP–raptor with DEPTOR cDNA from 
pRK5– Flag–DEPTOR (Addgene plasmid 21334) (Peterson, Laplante et al. 2009). 
mCherry–raptor was constructed by replacing YFP cDNA in YFP–raptor with mCherry 
cDNA from pmCherry–C1 (Clontech). 
III. 2. 3. Cell culture and transfection 
  HEK293 cells were grown in DMEM containing 10% (vol/vol) FBS at 37 °C with 
5% (vol/vol) CO2. All transfection experiments were performed when cells were 60– 
70% confluent in 6-cm plates. Transfection of plasmids was carried out using PolyFect 
(Qiagen) following the manufacturer’s recommendations. One day after transfection, 
cells (3.5 × 106) were lysed in 500 μL of ice-cold lysis buffer (40 mM Hepes, pH 7.5, 120 
mM NaCl, 10 mM pyrophosphate, 10 mM β-glycerophosphate, 2 mM EDTA, 1× 
protease inhibitor mixture, 0.3% CHAPS; designated “CHAPS buffer”) and analyzed by 
various assays. To establish the YFP–mTOR stable cell line, HEK293 cells were 
transfected with the YFP–mTOR plasmid, plated at low density for single-clone colonies 
to form, and selected in 500 μg/mL of G418. A cell clone expressing YFP–mTOR at a 
level comparable to that of endogenous mTOR was chosen. Endogenous mTOR was then 
knocked down by lentivirus-delivered shRNA (Addgene plasmid 1856) (Sarbassov, 
Guertin et al. 2005) as previously described (Yoon, Du et al. 2011), and selected by 1 
μg/mL of puromycin. For insulin stimulation, cells were cultured in serum-free medium 
for 24 h, followed by treatment with 100 nM insulin for 30 min. For glucose/glutamine, 
amino acids, or leucine stimulation, cells were cultured in glucose/ glutamine-free 
medium for 12 h, amino-acid-free medium for 2 h, or leucine-free medium for 1 h, 
followed by restimulation with glucose/glutamine for 1 h, amino acids for 30 min, or 
leucine for 15 min, respectively. 
 
III. 2. 4. Immunoprecipitation and in vitro kinase assay 
Cells were rinsed once with ice-cold PBS and lysed in ice-cold CHAPS buffer. 
The lysates were cleared by centrifugation at 10,000 × g for 10 min, and then subjected to 
immunoprecipitation at 4 °C with anti-HA beads or anti-Flag M2 beads for 2 h. For GFP 
or mTOR immunoprecipitation, anti-GFP or anti-mTOR (N-19) antibody was incubated 
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with the cell lysates for 2 h, followed by incubation with protein G beads for 1 h. The 
beads were washed three times with lysis buffer and then boiled in 2× SDS sample buffer 
for 5 min. Samples were analyzed by Western blotting. mTOR kinase assays were 
performed as previously described (Yoon, Du et al. 2011). mTORC1 kinase assays were 
carried out at 30 °C for 30 min in 25 mM Hepes (pH 7.4), 50 mM KCl, 10 mM MgCl2 
and 250 μM ATP, with 100 ng GST–S6K1 as the substrate. mTORC2 kinase assays were 
carried out at 37 °C for 30 min in 25 mM Hepes (pH 7.4), 100 mM potassium acetate, 1 
mM MgCl2, and 500 μM ATP, with 250 ng His–Akt as the substrate. 
III. 2. 5. Western blot analysis 
Cells were lysed in either CHAPS buffer or a buffer containing 20 mM Tris·HCl, 
pH 7.5, 0.1 mM Na3VO4, 25 mM NaF, 25 mM glycerophosphate, 2 mM EGTA, 2 mM 
EDTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 1× protease inhibitor 
mixture (Sigma-Aldrich), 0.3% Triton X-100. The lysates were cleared by centrifugation 
at 10,000 × g, then mixed with 2× SDS sample buffer and boiled for 5 min. Proteins were 
resolved on SDS/PAGE and transferred onto PVDF membrane (Millipore), followed by 
incubation with various antibodies according to the manufacturer’s recommendations. 
Detection of horseradish peroxidase-conjugated secondary antibodies was performed 
with Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer). Results were 
developed on X-ray films and scanned with an Epson scanner (Perfection 2400). 
III. 2. 6. In-cell cross-linking 
Chemical cross-linking was performed as described by Sancak et al. (9) Briefly, 
cells were grown in 6-cm plates and incubated with 3 mL of fresh culture media 
containing 1 mg/mL DSP (2.5 mM) for 10 min at 37 °C, and 5% CO2. DSP was prepared 
fresh as a stock solution of 250 mg/mL in DMSO. After the incubation time, DSP was 
quenched by adding Tris·HCl (pH 8.0) to a final concentration of 100 mM in fresh cell 
culture medium. After an additional 10-min incubation at 37 °C, 5% CO2 cells were 
washed on ice twice with cold PBS and lysed in 500 μL of lysis buffer (with CHAPS or 
Triton; see below). Cell lysates were diluted 50-fold and immediately infused into 
chambers for SiMPull analysis. 
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III. 2. 7. Single-molecule imaging and spot counting 
  Cells (3.5 × 106) growing in 6-cm plates were lysed in ∼500 μL CHAPS buffer or 
Triton buffer (40 mM Hepes, pH 7.5, 120 mM NaCl, 10 mM pyrophosphate, 10 mM β-
glycerophosphate, 2 mM EDTA, 1× protease inhibitor mixture, 0.3% Triton) to yield a 
final lysate concentration of 3.5 mg/mL (Bradford assay). For cell mixing experiments, 
cells were scraped in CHAPS buffer, mixed at 1:1 ratio, and then incubated on ice for 15 
min. Alternatively, cells were trypsinized and resuspended in PBS, mixed at 1:1 ratio, 
and then pelleted, followed by lysis in CHAPS buffer. Lysates were cleared by 
centrifugation at 10,000 × g for 10 min and diluted 20- to 100-fold (in most cases 50-
fold) to obtain a surface density optimal for single-molecule analysis (∼300 molecules in 
2,500 μm2 imaging area). Dilutions were made either in detergent-free lysis buffer or 20 
mM Tris, pH 8.0, 50 mM NaCl; similar results were obtained in both cases. A prism-type 
total internal reflection fluorescence microscope was used to acquire single-molecule 
data. Quartz slides were passivated with 200 mg/mL methoxy polyethylene glycol (PEG) 
containing 2.5% (wt/wt) biotinylated PEG. YFP- and mCherry-tagged proteins were 
excited at 488 nm and 568 nm, respectively. Band pass filters (HQ 535/30, Chroma 
Technology for YFP and BL 607/36, Semrock for mCherry) were used to collect the 
emitted fluorescence signal. All experiments were performed at room temperature (22–25 
°C) unless specified. Mean spot count per image (imaging area 2,500 μm2) and SD were 
calculated from images taken from 20 or more different regions. 
III. 2. 8. Photobleaching analysis and single-molecule colocalization 
Analysis were performed as previously reported (Jain, Liu et al. 2011; Jain, Liu et 
al. 2012). Briefly, single-molecule fluorescence time traces of surface immobilized YFP- 
tagged proteins were manually scored for the number of bleaching steps. To avoid false 
colocalization, samples were immobilized at an optimal surface density (∼300 molecules 
in 2,500 μm2 imaging area) by adjusting the dilution factor for each lysate. The 
fluorescence trace of each molecule was classified as having one to four bleaching steps 
or was discarded if no clean bleaching steps could be identified. At least 400 molecules 
were evaluated for each experiment; the total number of molecules successfully scored as 
bleaching in one to four steps (N) is depicted in the figures. The intensity of molecules 
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scored as bleaching in one and two steps was plotted to verify scoring: on average we 
expect the fraction of molecules bleaching in two steps to be twice as bright as the 
molecules bleaching in one step. The intensity of discarded molecules was also plotted to 
ensure unbiased scoring as observed via lack of enrichment of any specific intensities. To 
convert the photobleaching step distribution to monomer/dimer fraction, the percentage 
of molecules bleaching in two steps was compared with the calibration experiment in 
Figure III. 1I. This conversion was performed only when >90% of the molecules 
bleached in one or two photobleaching steps. For single-molecule colocalization, two 
separate images were acquired imaging YFP or mCherry in the same region of interest. 
Positions of YFP and mCherry molecules were determined to half-pixel accuracy by 
fitting a Gaussian point spread function. Molecules lying within 1-pixel distance (pixel 
size, ∼150 nm) were said to be colocalized. For determining false colocalization by 
chance, two different regions were imaged and similar analysis was performed; 
colocalization by chance was observed to be ∼1%. 
III. 2. 9. Statistical analysis 
All data are presented as mean ± SD, or representative images, of at least three 
sets of independent experiments. Whenever necessary, statistical significance of the data 
was analyzed by performing one-sample or paired t tests. 
 
III. 3. Results 
III. 3. 1. Assay validation and mTORC1 stoichiometry 
To study mTOR complexes by SiMPull, we deemed it important to establish a 
system where a fluorescently tagged mTOR can incorporate into endogenous complexes. 
To that end, we established a cell line stably expressing YFP–mTOR in which the 
endogenous mTOR was silenced by short hairpin RNA (Fig. III. 1A, henceforth called 
“YFP–mTOR stable cell line”). The YFP–mTOR protein associated with endogenous 
raptor and rictor (Fig. III. 1A). More importantly, the cell line faithfully recapitulated 
known regulations of mTOR signaling, such as insulin- and serum-stimulated 
phosphorylation of mTORC1 targets S6K1 and 4E-BP1, and mTORC2 target Akt, as 
well as amino acid dependence of S6K1 and 4E-BP1 phosphorylation (Fig. III. 1B and 
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Fig. III. 2A). When cell lysates from this line were applied to single-molecule imaging 
chambers coated with an antibody against raptor, YFP–mTOR fluorescence spots were 
observed, well above the background level of fluorescence seen in the control channel 
without the antibody (Fig. III. 1 C and D), illustrating specific pulldown of mTOR in 
complex with raptor, or mTORC1. 
To assess the sensitivity of SiMPull, we compared detection of YFP–mTOR by 
Western blotting and by SiMPull with cell lysates at the same concentrations. 
Remarkably, even at 1,000-fold dilution of the lysates SiMPull detected YFP–mTOR 
specifically (Fig. III. 3A), whereas at 100-fold dilution of the same lysates, there was no 
longer any signal on Western blots (Fig. III. 3B). Furthermore, in SiMPull, we were able 
to detect YFP–mTOR pulled down via endogenous raptor using a 100-fold dilution of the 
lysate (Fig. III. 3 C and D), whereas no signal was detected in conventional 
coimmunoprecipitation using the same dilution of lysate and raptor antibody (Fig. III. 
3E); SiMPull required only 50 μL of the extract as opposed to 500 μL used for the 
corresponding coimmunoprecipitation. Hence, the SiMPull method is highly sensitive 
compared with conventional biochemical methods. 
We then analyzed the fluorescence time trajectories of YFP–mTOR pulled down 
with raptor. Most molecules (96%) bleached in either one or two steps, indicating that 
mTORC1 contains one or two molecules of fluorescently active YFP–mTOR (Fig. III. 
1E). Nearly 60% of the molecules exhibited two-step bleaching, whereas 36% bleached 
in a single step. The molecules bleaching in two steps were nearly twice as bright as one-
step bleachers on average, indicating a reliable classification based on photobleaching 
steps (Fig. III. 1E). Previous studies have determined that fluorescent proteins may not all 
mature to completion and the fraction of fluorescently active YFP is ∼75% (Ulbrich and 
Isacoff 2007; Jain, Liu et al. 2011). In a calibration experiment, photobleaching step 
distribution of monomeric and dimeric YFP or a mixture of the two proteins was 
measured, which revealed that the fraction of two-step photobleaching spots is linearly 
proportional to the fraction of dimeric YFP included (Fig. III. 1 H and I). A comparison 
of the observed photobleaching step distribution of YFP–mTOR in mTORC1 to the 
calibration data suggested that nearly all mTORC1 complexes (>95%) contain two copies 
of YFP–mTOR, assuming the maturation level of YFP for all experiments is the same. 
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We also transiently coexpressed YFP–mTOR and HA–raptor, which assembled 
into functional mTORC1 complexes (Fig. III. 2B). Single-molecule fluorescence 
photobleaching analysis for YFP–mTOR pulled down with HA–raptor revealed that the 
complexes each contained two copies of YFP–mTOR (Fig. III. 4 A and B). Similarly, 
when YFP–raptor and Flag–mTOR were coexpressed (Fig. III. S1 C and D), two copies 
of YFP–raptor were found in each mTOR–raptor complex (Fig. III. 1 F and G). 
Additionally, the mTORC1 inhibitors PRAS40 and DEPTOR were also present in two 
copies per mTORC1 (Figs. 2 E–G and 4 C–F). 
To confirm that the complexes captured via SiMPull represent physiological state 
of mTORC1 and are not assembled/disassembled upon cell lysis, we followed the 
strategy of Riley et al. (Riley, Yario et al. 2012) and mixed lysates from cells expressing 
YFP–raptor and Flag–mTOR separately, and compared them to lysates of cells 
coexpressing the same proteins at similar expression levels (Fig. III. 4G). At least 10-fold 
more mTORC1 complexes were detected in the lysates from cotransfected cells than the 
mixed lysates (Fig. III. 4H). Similar results were obtained when intact cells were mixed 
before lysis (Fig. III. 4I). Thus, postlysis association of mTORC1 components does not 
significantly contribute to the complexes detected here via SiMPull. 
SiMPull requires dilution of cell lysates to achieve low pulldown density suitable 
for single-molecule analysis, which could lead to loss of weakly associated physiological 
complexes. To address this issue, we treated YFP–mTOR-expressing cells with the cross-
linker dithiobis(succinimidylpropionate) (DSP) before cell lysis. Lysis of cells using a 
Triton X-100–containing buffer disrupted mTORC1 complexes as expected (Kim, 
Sarbassov et al. 2002), whereas DSP cross-linking before cell lysis preserved the 
complex under the same lysis condition (Fig. III. 5 A and B), validating our cross-linking 
conditions. Importantly, cross-linked mTORC1 complexes exhibited a photobleaching 
step distribution corresponding to that of a dimer (Fig. III. 5C), suggesting that the 
physiological complexes are intact during SiMPull analysis without cross-linking. In 
summary, we find that mTORC1 is dimeric, containing two copies of each component. 
These findings are consistent with the previous cryo-EM data (Yip, Murata et al. 2010), 
thus validating our experimental system for analysis of mTOR complexes by SiMPull. 
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III. 3. 2. mTORC2 is dimeric 
mTORC2 assembly requires mSin and mLST8 (Frias, Thoreen et al. 2006; 
Guertin, Stevens et al. 2006) in addition to mTOR and rictor, but the oligomeric state of 
mTORC2 is under debate (Wullschleger, Loewith et al. 2005; Frias, Thoreen et al. 2006; 
Takahara, Hara et al. 2006; Tao, Barker et al. 2010). When all four core components of 
mTORC2 (mTOR, rictor, mSin, and mLST8) were coexpressed, each component self-
associated as indicated by coimmunoprecipitation of the recombinant protein with two 
different tags (Fig. III. 6A and Fig. III. 7A), suggesting that assembled mTORC2 is 
oligomeric. To determine the oligomeric state of mTOR in mTORC2, we captured 
mTORC2 complexes from the YFP–mTOR stable cell line on SiMPull surfaces using an 
antibody against endogenous rictor (Fig. III. 6B). Intriguingly, once again we observed a 
photobleaching pattern characteristic for dimeric YFP–mTOR (Fig. III. 6C). Similar 
results were obtained when YFP–mTOR was coexpressed with recombinant mTORC2 
components (Fig. III. 8 A and B), which also assembled into functional mTORC2 (Fig. 
III. 7 B and C).  
Next, we probed the stoichiometry of rictor in mTORC2. YFP–rictor was 
coexpressed with Flag–mTOR, mSin–HA and HA–mLST8, and the assembly of 
mTORC2 was verified by ensemble pulldown (Fig. III. 7 D and E). Upon single-
molecule pulldown of mTORC2 via Flag–mTOR (Fig. III. 6D), we observed YFP–rictor 
photobleaching consistent with two copies of rictor per mTORC2 (Fig. III. 6E). 
Furthermore, YFP–DEPTOR in mTORC2 was found to display photobleaching 
distribution that corresponded to a mixture of monomers and dimers (∼60% dimer) (Fig. 
III. 8 C and D), indicating that each mTORC2 can harbor up to two copies of DEPTOR. 
Once again, cell mixing (Fig. III. 8 E and F) and DSP cross-linking (Fig. III. 8 G 
and H) experiments were performed, the results of which confirmed that the dimeric 
stoichiometry most likely reflects physiological assembly of mTORC2 in live cells. In 
conclusion, our results unequivocally reveal mTORC2 as a dimer, in which each subunit 
is present in two copies. 
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III. 3. 3. mTORC1 and mTORC2 are mostly distinct but cocomplexes exist 
Biochemical characterizations so far suggest that mTORC1 and mTORC2 are 
mutually exclusive, but functional cross-talk between these two complexes at multiple 
levels is increasingly apparent (Dibble, Asara et al. 2009; Huang and Manning 2009; 
Julien, Carriere et al. 2010). Even a small fraction of mTORC1/mTORC2 cocomplex 
could be functionally significant, but may have escaped detection by conventional 
biochemical methods. Multicolor SiMPull should allow direct visualization of such 
hybrid complexes, if any. As a positive control, we coexpressed Flag–mTOR, mCherry–
raptor, and YFP–PRAS40. Upon capturing Flag–mTOR, we observed both mCherry–
raptor and YFP–PRAS40 fluorescence spots (Fig. III. 9A); ∼49% of YFP–PRAS40 spots 
colocalized with mCherry–raptor, indicating their coexistence in the same complexes. 
Incomplete colocalization between the two likely arises from incomplete chromophore 
maturation (∼40% for mCherry and ∼75% for YFP) (Ulbrich and Isacoff 2008; Dunne, 
Fernandes et al. 2009) and the participation of endogenous untagged proteins. 
Next, we coexpressed mCherry–raptor and YFP–rictor together with Flag–mTOR, 
mLST8, and mSin. An anti-Flag antibody captured both mTORC1 and mTORC2 as 
visualized by mCherry and YFP fluorescent spots, respectively, and about 7% of 
mCherry–raptor spots reproducibly colocalized with YFP–rictor (Fig. III. 9B). Taken into 
consideration the incomplete chromophore maturation mentioned above, it is likely that 
the true fraction of the mTORC1/mTORC2 cocomplex is higher than 7%. Under these 
experimental conditions, the colocalization by chance was ∼1% (Fig. III. 10A). 
Additionally, when YFP instead of YFP–rictor was expressed, only a background level of 
YFP fluorescent spots was observed upon Flag–mTOR pulldown, and these spots did not 
colocalize with mCherry–raptor (Fig. III. 10B). Importantly, raptor coexpression did not 
alter mTORC2 stoichiometry, as rictor was still present in two copies (Fig. III. 10C). 
To verify that the hybrid complex was not an artifact of cell lysis, we performed 
cell mixing experiments. mTORC1 components (Flag–mTOR and mCherry–raptor) and 
mTORC2 components (Flag–mTOR, YFP–rictor, mSin–HA, and HA–mLST8) were 
expressed in two separate pools of cells, which were mixed during lysis (Fig. III. 10 D–
F). After accounting for false colocalization by chance, only 2% colocalization between 
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mCherry–raptor and YFP–rictor was observed from mixed lysates. Therefore, although 
the two mTOR complexes are predominantly distinct, hybrid mTOR complexes 
containing both raptor and rictor or higher order assemblies of mTORC1/mTORC2 exist, 
albeit at a low level. 
 
III. 3. 4. mTORC1 and mTORC2 components are monomeric  
Because both mTORC1 and mTORC2 are dimeric, we asked if mTOR or other 
core components could self-dimerize. To that end, each component tagged with YFP was 
individually expressed. When YFP–mTOR was captured using an anti-mTOR antibody, 
nearly 75% of the molecules bleached in a single step, whereas 20% bleached in two 
steps, indicating that a majority of overexpressed mTOR was monomeric (Fig. III. 11A). 
Furthermore, when YFP–mTOR and HA–mLST8 were coexpressed and the mTOR–
mLST8 subcomplexes were captured through the HA tag, a photobleaching step 
distribution characteristic of monomers was observed for YFP–mTOR (Fig. III. 11B). 
Similar analysis for HA–YFP–raptor and HA–YFP–rictor, pulled down through the HA 
tag, also revealed monomeric distributions (Fig. III. 11 C and D). In addition, YFP–
PRAS40 bound to raptor was monomeric (Fig. III. 12 A and B). The observed small 
fractions of dimer may arise due to incorporation of YFP-tagged proteins in endogenous 
mTOR complexes. Taken together, our results show that although both mTORC1 and 
mTORC2 are exclusively dimeric, individual mTORC components and subcomplexes are 
predominantly monomeric. Thus, no single mTORC subunit serves as a dimerizing 
component. 
 
III. 3. 5. mTORC stoichiometry is unchanged under various physiological conditions 
 Next we asked if the oligomerization of mTOR complexes was affected by 
upstream signals or physiological conditions known to regulate mTOR signaling, 
including growth factors, nutrient availability, and cellular energy levels. To examine the 
effect of energy sufficiency, we starved the YFP–mTOR stable cells of glucose and 
glutamine, which leads to energy depletion and inhibition of mTORC1 signaling (Kim, 
Hoffman et al. 2013), and briefly (1 h) restimulated them with growth medium containing 
glucose and glutamine. As shown in Fig. III. 13A, a nearly equal number of mTORC1 
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complexes pulled down through endogenous raptor were detected by SiMPull, with 
similar photobleaching step distribution, under starvation and stimulation conditions. 
Similarly, neither amino acids (Fig. III. 13B) nor leucine (Fig. III. 12 C and D) 
stimulation had any effect on the number or stoichiometry of mTORC1. In addition, 
insulin stimulation did not affect mTORC1 (Fig. III. 13C) or mTORC2 assembly (Fig. 
III. 13D). The starvation and stimulation conditions impacted mTOR signaling as 
expected (Fig. III. 1B and Fig. III. 2A). These observations directly establish that 
inhibition of mTOR activity by energy stress or nutrient- or growth-factor depletion can 
be achieved without disassembly of the mTOR complexes. 
 
III. 3. 6. Effect of rapamycin on mTOR complexes 
Several models have been proposed for the mechanism by which rapamycin 
inhibits mTOR. For example, rapamycin may limit substrate access to the kinase domain 
(McMahon, Choi et al. 2002; Yang, Rudge et al. 2013), may induce raptor dissociation 
from mTOR (Kim, Sarbassov et al. 2002; Oshiro, Yoshino et al. 2004; Yip, Murata et al. 
2010), or displace a key regulator (Fang, Vilella-Bach et al. 2001). We investigated the 
effect of rapamycin on the stoichiometry of mTOR complexes. As reported (Sarbassov, 
Ali et al. 2006), short-term treatment of cells with rapamycin dissociated raptor from 
mTOR and inhibited mTORC1 signaling, whereas on prolonged treatment, mTORC2 
assembly was also affected (Fig. III. 14 A and B). When YFP–mTOR stable cells were 
treated with increasing concentrations of rapamycin (2–100 nM) for 30 min and 
mTORC1 complexes were captured from cell lysates through endogenous raptor, the 
number of YFP–mTOR pulled down decreased with increasing rapamycin dose (Fig. III. 
15A): treatment with 2 nM of rapamycin led to reduction by 56%, and a maximal 
reduction of ∼90% was reached by 10 nM and 100 nM rapamycin (Fig. III. 15C). The 
residual mTORC1 appeared to be resistant to rapamycin, consistent with previously 
reported observations (Kim, Sarbassov et al. 2002). Thus, acute rapamycin treatment at 
low dose disrupted the interaction between mTOR and raptor. 
Additionally, we found that the fraction of dimers decreased as the rapamycin 
dose was increased. At 2 nM of rapamycin, about 47% of the molecules bleached in two 
steps, whereas at 100 nM, only 29% of the molecules exhibited two-step bleaching (Fig. 
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III. 15B). The photobleaching analysis was performed at similar surface densities of the 
complexes (∼0.1 molecules⋅μm−2), precluding any artifacts due to differences in the 
immobilization density. This observation of transient monomeric mTOR–raptor 
complexes indicates that rapamycin disrupts mTORC1 in at least two steps, displacing 
one mTOR (or mTOR–raptor monomeric subcomplex) at a time. Consistent with these 
results, mTOR bound to FKBP12–rapamycin is monomeric, as indicated by the single-
step photobleaching exhibited by YFP–mTOR pulled down via surface immobilized 
FKBP12–rapamycin (Fig. III. 12 E and F). The reduction in mTORC1 signaling activity 
(pS6K1) corresponded with the loss of intact dimeric mTORC1 complexes (Fig. III. 
15C), implying that disruption of mTORC1 dimeric architecture contributes significantly 
to rapamycin-induced abrogation of mTORC1 signaling. 
Next, we investigated the effect of prolonged rapamycin treatment on mTORC2 
assembly by capturing endogenous rictor from YFP–mTOR cell lysates. The number of 
mTORC2 complexes decreased by 40% upon 6-h treatment with 100 nM of rapamycin 
and was reduced by 79% after 24 h (Fig. III. 15D). Interestingly, in contrast to the 
transient mTORC1 monomers, mTORC2 remained a dimer at all time points (Fig. III. 
15E). Rapamycin treatment did not affect mTOR expression levels (Fig. III. 14 C and D), 
whereas the amount of mTORC1 decreased (Fig. III. 14E). Thus, our results suggest that 
rapamycin does not directly affect mTORC2 stoichiometry. Instead, rapamycin may 
sequester free mTOR and subsequently impair mTORC2 assembly over time. 
 
III. 4. Discussion 
Using SiMPull we have determined the stoichiometry and assembly of mTOR 
complexes captured from whole cell lysates. In addition to confirming the dimeric 
structure of mTORC1 as previously revealed by cryo-EM studies, we find that mTORC2 
assembles into a dimer, with two copies of each subunit. Interestingly, all individual 
subunits of mTORCs including mTOR, when expressed alone, are monomeric. This 
excludes a commonly presumed role of the HEAT repeats in mediating mTOR self-
association. Interaction between mTOR and raptor alone is sufficient to form mTORC1 
dimers, but mTORC2 assembly and dimerization require coexpression of mSin and 
mLST8 in addition to mTOR and rictor. Under physiological conditions, there is no 
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evidence of monomeric interaction between mTOR and raptor or mTOR and rictor. 
Hence, we propose a model for mTORC assembly where the interaction between 
monomeric subunits is unstable; assembly requires multiple subunits to accumulate at 
high local concentrations (Fig. III. 15F), which may be facilitated by membrane 
localization, subcellular compartmentalization, or scaffolding proteins. The small but 
significant fraction of mTORC1–mTORC2 cocomplex revealed by SiMPull suggests a 
potential physical cross-talk between the two complexes that may have evaded detection 
by conventional biochemical methods. Future investigation examining the biological 
function of this cocomplex is warranted. 
Of significance, our SiMPull assays have captured the existence of monomeric 
mTORC1 (mTOR–raptor complex) upon acute rapamycin treatment, before complete 
disruption of the mTOR–raptor interaction (Fig. III. 15F). The capture of this 
intermediate state of mTORC1, which was not detected by cryo-EM analysis (Yip, 
Murata et al. 2010), further attests to the exquisite sensitivity of the SiMPull method. We 
also provide direct evidence that cellular stress conditions that abrogate mTORC1- or 
mTORC2-mediated signaling do not alter the number or oligomerization state of mTOR 
complexes, indicating that effective inhibition of mTOR signaling can be achieved 
without disassembling mTOR complexes. Of note, Kim et al. recently reported that 
glucose and glutamine deprivation results in monomeric mTORC1 (Kim, Hoffman et al. 
2013), which is not observed in our SiMPull assays. Again, direct experimentation with 
fresh cell lysates containing near-endogenous proteins, without any additional 
manipulation such as those required for conventional coimmunoprecipitation, may be 
advantageous in capturing physiologically relevant protein complexes. Dimerization of 
other PIKKs such as ATM and DNA-PK play important roles in the regulation of their 
activities (Bakkenist and Kastan 2003; Spagnolo, Rivera-Calzada et al. 2006). Our data 
reveals differences in assembly mode and regulation of mTOR compared with these 
members of the PIKK family. 
Over 75% of the proteins in a cell can oligomerize (Goodsell and Olson 2000). 
SiMPull is a powerful method to investigate oligomeric protein assemblies. This method 
provides direct and quantitative readout of the assembly state of the proteins, expressed at 
endogenous levels directly in their native context. Proteins are captured from freshly 
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lysed cells and probed at single-molecule resolution without requiring removal of other 
proteins, minimizing loss of interactions due to stringent wash steps associated with 
conventional immunoprecipitation. SiMPull worked wherever ensemble 
immunoprecipitation worked across the variety of constructs and samples tested in this 
study, highlighting the versatility of the assay. By performing SiMPull and biochemical 
analysis on the same samples, we were able to correlate the complex architecture with its 
functional activity. The advent of genetic engineering at endogenous loci and 
developments in short genetically encoded fluorescent tags should enable powerful 
applications of this technology to near-endogenous systems. 
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III. 5. Figures 
 
 	  
Figure III. 1. mTORC1 is dimeric. (A) Expression of mTOR in the YFP-mTOR stable 
cells (YM) (upper panels) and interaction with raptor and rictor assessed by co-IP (lower 
panels) are shown. Scr: scramble. (B) YM cells were stimulated with insulin, serum, or 
amino acids (AA). (C) Schematic depiction of mTORC1 SiMPull. (D) Endogenous raptor 
was pulled down from YM cells, followed by SiMPull analysis. Shown are schematic 
diagram (left), representative YFP fluorescence images (center), and average number of 
molecules per imaging area (Nf). (E) Distribution of fluorescence photobleaching steps 
(left) and corresponding intensity (a.u.: arbitrary units) distribution (right) for samples 
described in (D). N, total number of molecules analyzed. (F) Flag-mTOR and HA-YFP-
raptor were co-expressed and Flag-mTOR was pulled down, followed by analyses similar 
to those in (D). (G) Same analyses as in (E) for samples described in (F). Scale bar: 5 μm. 
(H) Monomeric YFP (mYFP) and tandem dimeric YFP (tdYFP) were mixed in the ratios 
as indicated and single molecule fluorescence time-trajectories were analyzed. Top: 
number of fluorescence photobleaching steps. Bottom: intensity (Int., arbitrary units) of  
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Figure III. 1 (Cont.) 
molecules exhibiting 1 or 2 photobleaching steps. (I) Observed fraction of two-step 
bleaching events changes linearly with the fraction of tdYFP.  
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	   61 
 
 
 
Figure III. 2. Characterization of fluorescent protein-tagged mTORC1 subunits.  
(A) YFP-mTOR stable cells were deprived of glucose/glutamine for 12 h, amino acids for 
2 h, or leucine for 1 h, and then restimulated by complete growth medium for 1h 
(glucose/glutamine), 30 min (amino acids), or 15 min (leucine). (B) HA-raptor and YFP-
mTOR were co-expressed in HEK293 cells and YFP immunoprecipitates from cell 
lysates were subjected to mTORC1 kinase assay using GST-S6K1 as substrate.  
(C) Empty vector, YFP-raptor or mCherry-raptor was transfected into HEK293 cells. Cell 
lysates were subjected to HA immunoprecipitation followed by Western blotting.  
(D) HA-YFP-raptor and Flag-mTOR were co-expressed in HEK293 cells and HA 
immunoprecipitates from cell lysates were subjected to mTORC1 kinase assay. (E) HA-
PRAS40 or HA-YFP-PRAS40 were transiently expressed in HEK293 cells and cell 
lysates were subjected to HA immunoprecipitation. Endogenous mTOR and raptor were 
detected by Western blotting. (F) Empty vector, HA-PRAS40, or HA-YFP-PRAS40 were 
co-expressed with myc-S6K1 in HEK293 cells. pT389-S6K1, myc-S6K1, and PRAS40 
were detected by Western blotting. (G) HA-DEPTOR or HA-YFP-DEPTOR were 
transiently expressed in HEK293 cells and cell lysates were subjected to HA 
immunoprecipitation. Endogenous rictor and raptor were detected by Western blotting. 
	   62 
 
 
Figure III. 3. Comparison of sensitivity of SiMPull and Western blotting (WB).  
(A, B) Comparison of SiMPull with WB. Lysate from YFP-mTOR cells was diluted as 
indicated. In SiMPull, YFP-mTOR was captured using an antibody against GFP. WB was 
performed using the same anti-GFP antibody, or an antibody against mTOR.  
(C-E) Comparison of SiMPull with co-immunoprecipitation. (C, D) Lysate from YFP-
mTOR cell line was diluted as indicated and applied to SiMPull chambers coated with an 
antibody against raptor. (E) Conventional immunoprecipitation for raptor using various 
dilutions of YFP-mTOR expressing cells, followed by WB for mTOR and raptor. 
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Figure III. 4. mTORC1 is dimeric. Epitope-tagged mTORC1 components were 
transiently expressed and captured on single-molecule imaging chambers as depicted in 
schematics (A, C, E left). (A,B) YFP-raptor and mTOR formed dimers when co-
expressed. (C, D) PRAS40 when pulled down via mTOR was dimeric. (E, F) DEPTOR 
associated with mTORC1 was dimeric. (G) YFP-Raptor and Flag-mTOR were co-
transfected (CT), or transfected separately (Raptor, mTOR). For Mixed, lysates 
expressing mTOR and raptor separately were mixed at a 1:1 ratio. Expression 
levels in these lysates were analyzed by Western blotting. (H) SiMPull analysis of 
mTOR-Raptor interaction in lysates in (G). (I) Cells were transfected as in (G&H). For 
Mixed, cells were trypsinized and mixed at 1:1 raito, followed by lysis. SiMPull analysis 
was performed as in (H). Error bars depict standard deviation of the mean across 20 or 
more imaging areas. Scale bars: 5μm.  
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Figure III. 5. mTORC1 crosslinking assay. (A-B) YFP-mTOR stable cells were lysed 
in buffer containing 1% Triton X-100 or 0.3% CHAPS. For crosslinking, cells were 
treated with DSP crosslinker prior to cell lysis. mTORC1 was pulled down using anti-
raptor antibody. (C) Fluorescence photobleaching step distribution for YFP-mTOR in 
mTORC1, for cells lysed in 0.3% CHAPS without or with DSP. Error bars depict 
standard deviation of the mean over > 20 images. Scale bar: 5 μm. 
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Figure III. 6. mTORC2 is dimeric. (A) mTOR oligomerizes in mTORC2 shown by co-
IP. (B, C) SiMPull for endogenous rictor from YM cells and analysis similar to Fig. III. 
1D and E. (D, E) YFP-rictor was co-expressed with Flag-mTOR, mSin and mLST8, and 
Flag-mTOR was pulled down. SiMPull data are presented as in (B, C). Scale bar: 5 μm. 
  
	   66 
 
 
Figure III. 7. mTORC2 oligomerization and incorporation of fluorescently labeled 
subunits. (A) Recombinant proteins were transiently expressed in HEK293 cells as 
indicated, followed by Flag or HA immunoprecipitation and Western blotting.  
(B) Recombinant proteins were transiently expressed in HEK293 cells as indicated, 
followed by Flag immunoprecipitation and Western blotting. (C) Recombinant proteins 
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Figure III. 7 (Cont.)  
were transiently expressed in HEK293 cells as indicated, followed by GFP 
immunoprecipitation and in vitro mTORC2 kinase assays using Akt as a substrate.  
(D) Recombinant proteins were transiently expressed in HEK293 cells as indicated, 
followed by Flag immunoprecipitation and Western blotting. (E) Recombinant proteins 
were transiently expressed in HEK293 cells as indicated, followed by HA 
immunoprecipitation and in vitro mTORC2 kinase assay using Akt as a substrate. 
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Figure III. 8. mTORC2 is dimeric. (A) YFP-mTOR was co-expressed with mSin-HA, 
HA-mLST8 and Flag-rictor. mTORC2 complexes were captured on SiMPull using Flag 
antibody. (B) Fluorescence photobleaching step distribution (left) and intensity of scored 
molecules (right) for YFP-mTOR in mTORC2. (C) YFP-DEPTOR was co-expressed 
with core mTORC2 components in HEK293 cells, and was pulled down via Flag-rictor 
(D) Fluorescence photobleaching step distribution (left) and intensity of scored molecules 
(right) for YFP-DEPTOR in mTORC2. (E) mTORC2 subunits were co-transfected (CT) 
or transfected separately (Rictor/mSin and mTOR/mLST8) followed by lysate mixing at 
1:1 ratio (Mixed). Expression levels were analyzed by Western blotting. (F) mTORC2 
from CT, Mixed, and Rictor/mSin lysates was capture using Flag antibody. Upper panels: 
for Mixed, lysates were mixed at a 1:1 ratio. Lower panels: for Mixed, cells were 
trypsinized and mixed at 1:1 ratio, followed by lysis. (G) YFP-mTOR stable cells were 
lysed in CHAPS buffer. Some cells were incubated with DSP crosslinker prior to cell 
lysis. mTORC2 as pulled down using anti-Rictor antibody. (H) Fluorescence 
photobleaching step distribution was analyzed for samples in (G). Scale bar: 5 µm. 
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Figure III. 9. mTORC1 and mTORC2 co-localization. (A) Flag-mTOR co-captures 
YFP-PRAS40 (left) and mCherry-raptor (center). Overlay of the two images (right) 
showed 49 ± 2% co-localization. (B) Flag-mTOR, mCherry-raptor, YFP-rictor, HA- 
mLST8 and mSin-HA were co-expressed. Flag-mTOR was pulled down, and YFP (rictor, 
left) and mCherry (raptor, center) were imaged. Overlay of the two images (right) 
showed 7 ± 3% co-localization across 6 independent experiments. Scale bar: 10 μm.  
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Figure III. 10. Two-color SiMPull for mTORC1 and mTORC2. (A) mCherry-raptor 
and YFP-rictor were co-expressed with Flag-mTOR, mSin-HA and HA-mLST8. Flag-
mTOR is captured using a surface immobilized Flag antibody. Two different imaging 
areas were visualized for YFP and mCherry to estimate the overlap by chance. The 
observed overlap was ~1% across 23 imaging areas over 4 independent experiments.  
(B) mCherry-raptor, YFP, Flag-mTOR, mSin-HA and HA-mLST8 were co-expressed. 
Flag-mTOR is captured using a surface immobilized Flag antibody. A background level 
of fluorescence was observed in the YFP channel and these fluorescent spots did not     
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Figure III. 10 (Cont.)  
colocalize with mCherry (0% overlap). (C) Fluorescence photobleaching step distribution 
for YFP-rictor from (A). (D) Expression levels of mTORC components when mTORC1 
and mTORC2 were expressed together, separately, or when lysates mixed at 1:1 ratio.  
(E) Top panel, colocalization of mTORC1 and mTORC2 when co-transfected in the same 
cells. Lower panel, colocalization of mTORC1 and mTORC2 when cell lysates are 
mixed. On capturing Flag-mTOR, YFP-rictor (left), mCherry-raptor (center), and 
overlapping spots (right) were observed. (F) The box plot shows distribution of overlay 
percentage from three independent experiments (N = 15 images) calculated after 
subtracting the false co-localization. Mean is shown as square marker and median as 
center line. Scale bar: 5 μm. 
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Figure III. 11. mTORC components are monomeric. (A) YFP-mTOR, (B) YFP-
mTOR and HA-mLST8, (C) HA-YFP-raptor or (D) HA-YFP-rictor were expressed in 
HEK293 cells, and captured on SiMPull surfaces as depicted (diagrams on left). The 
number of molecules observed per imaging area (center), and the distribution of 
fluorescence photobleaching steps (right) are shown.  
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Figure III. 12. mTOR sub-complexes are monomeric. (A) YFP-PRAS40 and Flag-
raptor were coexpressed and SiMPull was performed with Flag antibody. (B) YFP-
PRAS40 bound to raptor was monomeric as indicated by photobleaching step 
distribution. (C) YFP-mTOR stable cells were starved (-) leucine (Leu) for 1 h followed 
by re-stimulation (+) with leucine for 15 min. mTORC1 was pulled down via endogenous 
raptor followed by SiMPull analysis. (D) mTORC1 dimeric stoichiometry did not change 
upon leucine stimulation. (E) Lysate from YFP-mTOR stable cells was applied to 
SiMPull chambers coated with purified FKBP12 with or without rapamycin. YFP-mTOR 
was captured via FKBP12 in the presence of rapamycin. (F) YFP-mTOR bound to 
FKBP12-rapamycin was monomeric as indicated by photobleaching step distribution.  
Scale bars: 5 μm. 
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Figure III. 13. Effect of physiological stimulations on mTORCs. YFP-mTOR stable 
cells were starved (-) of (A) glucose and glutamine (Gluc/gln) for 12 h, (B) amino acids 
(AA) for 2 h or (C, D) serum for 24 h, followed by re-stimulation (+) with 
glucose/glutamine for 1 h, amino acids for 30 min, or 100 nM insulin for 30 min, 
respectively. mTORC1 (A-C) or mTORC2 (D) was pulled down via endogenous raptor 
or rictor, respectively, followed by SiMPull analysis.  
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Figure III. 14. Effect of rapamycin on mTOR complexes. (A) HEK293 cells were 
treated with 2, 10 or 100 nM rapamycin for 30 min. Cell lysates were analyzed by 
Western blotting with the indicated antibodies. (B) Cells were treated with 100 nM 
rapamycin for 0, 2, and 24 h. Cell lysates were subjected to mTOR immunoprecipitation, 
and analyzed by Western blotting. (C) YFP-mTOR stable cells were treated with various 
doses of rapamycin for 30 min, and SiMPull was performed with an antibody against 
endogenous mTOR. (D) YFP-mTOR stable cells were treated with 100 nM rapamycin 
for various lengths of time, and SiMPull was performed with an antibody against 
endogenous mTOR. (E) Cells were treated as in (D), and SiMPull was performed with an 
antibody against endogenous raptor. Error bars in (C-E) represent standard deviation of 
the mean across 20 or more imaging areas. Scale bar: 5 μm. 
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Figure III. 15. Effect of rapamycin on mTORCs. YFP-mTOR stable cells were treated 
with (A-C) increasing doses of rapamycin (Rap) for 30 min or (D-E) 100 nM rapamycin 
over the indicated time course. mTORC1 (A, B) and mTORC2 (D, E) were captured via 
endogenous raptor and rictor, respectively. Representative SiMPull images and number 
of molecules observed per imaging area are shown in (A, D). Scale bar: 5 μm. 
Distributions of fluorescence photobleaching steps are shown in (B, E). N, total number 
of molecules analyzed. (C) Left: relative levels of mTOR, mTOR-raptor (total), and 
mTOR-raptor (dimer) were obtained from SiMPull. Right: phosphorylation of S6K1 
(pT389) was measured by Western blotting under similar conditions, and quantified by 
densitometry. TPT: time post treatment. (F) A model for the assembly of mTOR 
complexes. Individual mTORC components are monomeric and assemble into homo-
dimeric holocomplexes, mTORC1 or mTORC2. Rapamycin directly disrupts the mTOR-
raptor interaction leading to monomeric mTORC1 and single proteins. Rapamycin-
FKBP12-associated mTOR cannot be incorporated into mTORC1 or mTORC2, resulting 
in indirect depletion of mTORC2 over time. 
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CHAPTER IV 
Single-molecule analysis of lipid-protein interactions in crude cell lysates 
 
IV. 1. Introduction 
Lipid second messengers represent a small fraction of the cell membrane and 
organelles, and their levels are precisely controlled. They play essential signaling roles in 
diverse cellular processes such as cell growth, proliferation, metabolism, and 
differentiation (Wymann and Schneiter 2008). Phosphoinositides constitute a well-known 
group of signaling lipids, which play fundamental roles in cells. Phosphatidylinositol 3-
phosphate (PI(3)P) is a well-studied phosphoinositide that is involved in endocytic and 
phagocytic trafficking, autophagy, and growth factor signaling (Gillooly, Morrow et al. 
2000; Burman and Ktistakis 2010; Yoon, Du et al. 2011). Phosphatidylinositol 4,5-
bisphosphate (PIP2) is involved in the regulation of cell shape, migration, cytokinesis, and 
membrane trafficking events (Di Paolo and De Camilli 2006). Phosphatidylinositol 3,4,5-
triphosphate (PIP3) is found at low levels at the plasma membrane but is dramatically 
increased by growth factor stimulation (Hawkins, Jackson et al. 1992). PIP3 is involved in 
cell proliferation, survival, metabolism, and it is implicated in diseases such as diabetes 
and cancer (Cantley 2002). Another important signaling lipid is phosphatidic acid (PA), 
which is involved cytoskeletal rearrangement, cellular trafficking for secretion and 
endocytosis, and growth factor signaling (Jenkins and Frohman 2005).  
 These signaling lipids are recognized by conserved lipid-binding domains (LBDs) 
that are widely present in proteins (DiNitto, Cronin et al. 2003). For example, FYVE 
domain has a conserved basic amino acid motif (RR/KHHCR) that contributes to a 
shallow, positively charged binding pocket for PI(3)P. PH domains exhibit a range of 
lipid selectivity depending on the amino acid residues present and on the cellular context. 
The PH domain of PLCδ is a specific effector for PIP2 (Lemmon, Ferguson et al. 1995) 
while the PH domain of Akt binds preferentially to PIP3, with an affinity in the 
nanomolar range (James, Downes et al. 1996; Frech, Andjelkovic et al. 1997; Rowland, 
Gong et al. 2012). In some instances, the LBD is not a well conserved module, as in the 
case of PA binding proteins, where the region involved in binding varies in sequence and 
structure from protein to protein, although a common feature is the presence of positively 
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charged amino acids that form electrostatic interactions with the head group of PA (Stace 
and Ktistakis 2006).  
Several in-vitro ensemble assays such as surface plasmon resonance, isothermal 
titration calorimetry, size-exclusion chromatography, and centrifugation-based methods 
have traditionally been employed to investigate lipid-protein interactions to determine 
binding affinities of LBDs, and a handful of studies have probed these interactions with 
single-molecule resolution (Scott, Musselman et al. 2012).  A major limitation of these 
studies lies in using purified recombinant proteins, which does not recapitulate the 
intracellular environment of a cell. Additionally, these assays typically require the 
separation of the unbound protein or lipid from the lipid-protein complex and therefore 
are not performed under equilibrium conditions. We previously reported the development 
of a single-molecule pulldown assay (SiMPull) to study protein complexes directly 
captured from cell lysates (Jain, Liu et al. 2011). In SiMPull, protein complexes are 
pulled down from freshly prepared cell lysates for single-molecule total internal 
reflection fluorescence microscopy. When proteins are stoichiometrically labeled, for 
example using fluorescent protein tags, SiMPull can reveal the stoichiometry of the 
protein complexes via single-molecule fluorescence photobleaching step analysis (Jain, 
Liu et al. 2011).  
  Here we present a novel approach based on the principle of SiMPull to interrogate 
lipid-protein interactions in crude cell lysates. We provide evidence of high sensitivity 
and specificity of our assay for a variety of LBDs and the full-length protein Akt. We 
also uncover new insights into the assembly of the LBDs and Akt on lipid vesicles.  
 
IV. 2. Materials and methods 
IV. 2. 1. Antibodies and reagents 
 All antibodies used were obtained from commercial sources as follows: mouse anti-
GFP from Roche and Rockland Immunochemicals; biotinylated mouse anti-GFP from 
Jackson ImunoResearch Labs. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-L-serine (POPS), 1,2-dioleoyl-sn-clycero-3-phopho-(1′-myo-inositol-
4′,5′-bisphosphate) (PIP2), 1,2-dioleoyl-sn-clycero-3-phopho-(1′-myo-inositol-3′,4′,5′-
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trisphosphate) (PIP3), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(Cap 
Biotinyl) (biotinPE) were from Avanti Lipids Inc. Phosphatidylinositol-3-phosphate 
(PI(3)P) was from Echelon Biosciences Inc. 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine perchlorate (DiD) was from Invitrogen. Purified GFP 
protein was from Abcam (ab84191). 
 
IV. 2. 2. Plasmids 
 The GFP-2xHrs-FYVE construct was previously reported by the Stenmark 
laboratory (Gillooly, Morrow et al. 2000). GFP-2xSpo20-PABD was from the Du 
laboratory at The University of Texas Health Science Center at Houston (Zeniou-Meyer, 
Zabari et al. 2007) The following plasmids were obtained from Addgene: GFP-PLC-PH 
(#21179) (Botelho, Teruel et al. 2000), 2xPH-PLC-GFP (#35142) (Bohdanowicz, Cosio 
et al. 2010), GFP-Akt (#39531), and GFP-Akt-PH (#39533) (Watton and Downward 
1999). GFP-Akt mutants (T308D/S473D; T308A/S473A; T308A/S473D; T308D/S473A) 
were created using QuickChange II mutagenesis kit (Stratagene). GFP-1xSpo20-PABD 
and GFP-1xHrs-FYVE were created by inserting a single copy of Spo20-PABD and Hrs-
FYVE, respectively, into a gateway destination plasmid pCDNA5 with AttR1/R2 
recombination sites and GFP fused at the N-terminus.  
 
IV. 2. 3. Cell culture, transfection, and cell lysis 
HEK293 cells were cultured in DMEM containing 10%(vol/vol) FBS at 37 °C 
with 5% (vol/vol) CO2. Cells seeded in 6-well plates were transfected at 70-80% 
confluency with various plasmids (3 µg each well) using PolyFect following the 
manufacturer’s recommendation (Qiagen). After 24 hr, cells were wash twice in ice-cold 
PBS and re-suspended in 150 µL per well of detergent-free buffer (40mM Hepes, pH 8, 
150mM NaCl, 10mM ß-glycerophosphate, 10mM sodioum pyrophostate, 2mM EDTA, 
1x Sigma protease inhibitor cocktail). Cells were lysed by passing 11 times through a 
25G1 needle (BD PrecisionGlide), followed by centrifugation for 20 min at 14,000 xg to 
remove cell debris. The concentrations of GFP-fused LBDs in cell lysates were 
determined by western blotting followed by quantification of x-ray band intensities using 
the ImageJ software, with purified recombinant as GFP reference. All GFP-LBDs were 
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present at 2-3 µM in cell lysates in our study. Lysates were then diluted 10 to 100-fold 
with dilution buffer (20mM Tris·HCl , pH 8, 150mM NaCl) before loading into the 
imaging chamber. 
 
IV. 2. 4. Vesicle preparation 
Lipids in chloroform (0.5 µmol total) were dried under nitrogen gas, and 
resuspended in 300 µL vesicle buffer (10mM Tris·HCl, pH 8, 150mM NaCl) to a final 
concentration of 1.66 mM. Vesicles were formed by water bath sonication followed by 
probe sonication. Unilamellar vesicles were collected as the supernatant after 
ultracentrifugation at 194,398xg in a TLA100.3 rotor for 2hr at 25°C. Lipid compositions 
for the phosphoinositide vesicles were 5% PI(3)P, PIP2, or PIP3, 95% 
phosphatidylcholine (PC) as a carrier, 0.05% biotin-phosphatidylethanolamine (biotin-
PE) for immobilization of the vesicles on imaging surface, and 0.1% C-18 DiD for 
fluorescence imaging of the vesicles. The composition of PA vesicles was similar as 
above except with 20% PA and 80% PC. Vesicles were diluted 500-fold to yield ∼700 
vesicles per 2,500 µm2, loaded into imaging chamber, and incubated for 20 min before 
loading of cell lysates. 
 
IV. 2. 5. Single-molecule imaging and quantification 
A prism-type total internal reflection fluorescence microscope was used to acquire 
single-molecule data. Quartz slides were passivated with methoxy polyethylene glycol 
(PEG). The surfaces were doped with 2-5% biotinylated PEG. Immobilized DiD-labeled 
vesicles were excited at 647 nm and GFP-tagged LBDs were excited at 488 nm. Band 
pass filters (red dichroic 635 plus a 665 long pass from Semrock for DiD, and HQ 535/30 
from Chroma Technology for GFP) were used to detect emission signal. All experiments 
were performed at room temperature (22–25°C).  
Number of molecules, S, were determined by quantifying the number of GFP and 
DiD spots per imaging area (2,500 µm2). The emission signal from each spot was 
recorded for 16 frames (100 ms each) and an intensity average calculated. Standard 
deviation was calculated from data collected from 10 or more different imaging areas. 
Cell lysate was present in the flow chamber during data acquisition.  
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IV. 2. 6. Single molecule co-localization 
The percentage of colocalization between vesicles and proteins was quantified by 
determining the number of molecules, S, and position of each DiD and GFP spot present 
in the same imaging region. Positions of DiD and GFP spots were determined to 2-pixel 
accuracy by fitting a Gaussian point spread function. Spots lying within 2-pixel distance 
(pixel size, 150 nm) were considered to be co-localized. The percentage of GFP-positive 
spots that overlapped with DiD spots was calculated. To determine false co-localization 
by chance, two different regions were imaged for DiD and GFP, and similar analysis was 
performed. Co-localization by chance was observed to be ~6%. 
 
IV. 2. 7. Single-molecule analysis for assembly plots 
 After addition of cell lysates into imaging chambers, several movies of 200-500 
frames were recorded at different incubation times. The first 50 frames were taken with 
647-laser excitation to localize DiD-labeled vesicles, followed by additional frames taken 
with 488-laser excitation to detect GFP molecules. Single-molecule fluorescent traces 
obtained from the movies were divided in three different categories: empty vesicles (only 
DiD signal), bound vesicles (DiD and GFP signals), and non-specifically bound GFP 
(only GFP signal). Single-molecule fluorescence traces showing DiD and GFP signal 
(bound vesicles) were further analyzed by Chung-Kennedy filtration algorithm to remove 
noise from raw GFP intensity profiles. Filtrated traces were manually scored for the 
number of bleaching steps to determine the number of GFP molecules per vesicle, NGFP. 
The fluorescence traces were classified as having 1–10 bleaching steps. The fraction of 
vesicles bound (Fv) was calculated from the number of empty vesicles and bound 
vesicles. NGFP per vesicle at different incubation times were used to build the assembly 
plots. 
 To determine the stoichiometry of vesicle-free proteins, GFP-LBDs in cell lysates 
were captured using biotinylated GFP antibodies immobilized to the surface via biotin-
NeutrAvidin interaction. Copy number of GFP was determined by photobleaching step 
analysis as described above. To avoid false colocalization, samples were immobilized at a 
surface density of (∼400 molecules per 2,500 µm2 imaging area) by adjusting the dilution 
factor for diluting each lysate (1000 to -5000- fold). The fluorescence trace of each 
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molecule was classified as having one to four bleaching steps or was discarded if no 
clean bleaching steps could be identified. At least 300 molecules were evaluated for each 
experiment; the total number of molecules successfully scored as bleaching in one to four 
steps is depicted in the figures.  
 
IV. 3. Results 
IV. 3. 1. Detection of lipid-protein interaction in crude mammalian cell lysates 
To establish a single-molecule assay for lipid-protein interactions in crude cell 
lysates, we chose three signaling lipid and LBD pairs that have been reported to display 
specific interactions: PI(3)P and Hrs-FYVE domain (Gillooly, Morrow et al. 2000); PIP2 
and PLCδ-PH domain (Lemmon, Ferguson et al. 1995); PA and Spo20-PABD domain 
(Nakanishi, de los Santos et al. 2004). Small unilamellar vesicles were prepared 
containing each of these signaling lipids and PC as a carrier, biotinylated 
phosphatidylethanolamine (biotin-PE) for immobilizing the vesicles on imaging surfaces, 
and C18-DiD to label the vesicles fluorescently. The vesicles were immobilized on 
biotin-polyethylene glycol (biotin-PEG)-passivated microscopic slides aided by 
NeutrAvidin at a density that allowed single-vesicle resolution. The LBDs were 
expressed in HEK293 cells as GFP-fusions of tandem repeats (i.e., 2xFYVE, 2xPH, and 
2xPABD), which have been commonly used as specific lipid sensors (Balla and Varnai 
2002). Detergent-free cell lysates expressing the LBDs were added to chambers of slides 
coated with the vesicles, and TIRF microscopy was performed to visualize vesicles via 
DiD and bound proteins via GFP. A schematic of the method is depicted in Figure IV.1A. 
The number of DiDs incorporated into each vesicle was determined by single-step 
photobleaching analysis, with most vesicles containing 6-8 dyes (Fig. IV.2), which is in 
agreement with the concentration of DiD used and the expected size of vesicles. 
As shown in Figure IV.1B, when lysates expressing the 2xFYVE sensor were 
added to various vesicles, we observed single-vesicle GFP fluorescent spots specifically 
in the PI(3)P-containing vesicles; all other vesicles displayed only background levels of 
GFP signals coming from surface impurities or nonspecific binding to the surface. 
Quantification of the GFP and DiD fluorescent spots are shown in Figure IV.1C. 
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Similarly, specific binding was observed from lysates expressing 2xPABD and 2xPH to 
PA and PIP2 vesicles, respectively (Fig. IV. 1D-G).  
To confirm that LBDs were indeed captured by vesicles and not interacting non-
specifically with the surface, we super-imposed the DiD images of vesicles with the 
corresponding GFP images of the LBDs, and found ~50-60% of GFP molecules 
colocalized to vesicles (Fig. IV. 3A-D). The colocalization did not reach 100% most 
likely because of unlabeled vesicles, inactive chromophores and surface impurities. 
Colocalization occurring due to chance was determined by overlapping DiD and GFP 
images from two different regions and was found to be approximately 6%. In summary, 
our assays detected lipid-protein interactions from whole cell lysates with high 
specificity. 
 
IV. 3. 2. Acquisition of assembly properties for LBDs  
Next, we sought to determine the binding dynamics of each LBD to its target 
phospholipid vesicles.  Using single-molecule TIRF microscopy we monitored binding-
dissociation events of the GFP-LBDs with the immobilized vesicles. We obtained two-
minute duration movies, where DiD was first briefly excited followed by longer GFP 
excitation (Fig. IV.4A).  This strategy allowed us to eliminate GFP spots derived from 
surface impurities and LBDs bound to unlabeled vesicles. Therefore, we could monitor in 
real-time only LBDs that were bound to labeled vesicles. The movies were acquired after 
incubating LBD-expressing lysates with vesicles for different times ranging from 0 to 30 
minutes. Cell lysates were present in the flow chamber during movie acquisition to 
ensure that any transient binding events were also captured.  
For all the single-molecule analyses we obtained two parameters: the fraction of 
LBD-bound vesicles (Fv), and the number of LBDs per vesicle (NGFP) derived from the 
number of photobleaching steps of GFP. The percentage of vesicles with a particular 
number of LBD-bound molecules was then calculated. Because the noise in single-
molecule traces of GFP made it difficult to clearly distinguish real photobleaching steps 
from inherent noise in GFP fluorescence (Dickson, Cubitt et al. 1997), we used Chung-
Kennedy filtration algorithm to average out noise from the raw GFP intensity profiles 
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(Chung and Kennedy 1991) (Fig. IV. 4B,C). This enabled us to count clearly the number 
of photobleaching steps when more than 4 molecules were bound (Fig. IV.4D).  
Applying this analysis scheme, we observed over an incubation time course 
increased binding of 2xFYVE to PI(3)P vesicles (Fig. IV. 5A), as well as NGFP, reflected 
by an increase in brightness of GFP spots (Fig. IV. 5B, left panels). Single-vesicle 
fluorescent traces of 2xFYVE revealed two distinct binding behaviors: transient binding 
of one 2xFYVE per vesicle and stable binding of multiple 2xFYVE per vesicle (Fig. IV. 
5B, right panels). The increase in NGFP over time is more clearly depicted in Figure IV. 
5C. Immediately after the loading of lysates, most vesicles (~80%) were unbound and a 
few (~10%) had one or two proteins per vesicle. After 30 minutes of incubation, more 
than half of the vesicles were occupied by two to 5 proteins.  
We next analyzed 2xPABD binding to PA vesicles. The fraction of bound 
vesicles, Fv, increased with the incubation time, although at a different rate from 2xFYVE 
(Fig. IV. 5A). At the same time, NGFP also increased, as reflected by an increase in 
brightness of GFP spots (Fig. IV. 5D, left panels). Single-vesicle fluorescent traces at 
three different incubation times revealed that 2xPABD assembled stably onto PA 
vesicles, without transient binding events as observed for 2xFYVE (Fig. IV. 5D, right 
panels). The percentage of vesicles with various NGFP was plotted over incubation time as 
shown in Figure IV. 5E. Immediately after the addition of 2xPABD lysate, we observed 
unbound vesicles (40%) and vesicles with one copy of the protein (37%) . Over time, 
more vesicles became populated with multiple copies of 2xPABD, such that by 30 
minutes almost 90% of the vesicles had two or more copies of the protein.  
Analysis of 2xPH interaction with PIP2 vesicles revealed two distinct populations 
of vesicles that displayed stable and transient binding, respectively (Fig. IV. 5F). 
Interestingly, although the fraction of bound vesicles, Fv, increased over incubation time 
(Fig. IV. 5A), the number of proteins per vesicle, NGFP, did not change markedly (Fig. IV. 
5G). Most vesicles had one (50%) and two copies (25%) of 2xPH bound, and only 16% 
vesicles had three copies by 30 minutes. To rule out the possibility that the GFP-tagged 
fusion proteins might oligomerize independent of vesicle binding, we analyzed the 
stoichiometry of tandem LBDs pulled down by an anti-GFP antibody under the same 
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conditions as above. As shown in Figure IV. 6A-C, all these fusion proteins were 
monomeric in the absence of vesicles. 
 
IV. 3. 3. Assembly of lipid binding domains in a monomer configuration  
Having established our assay to study lipid-protein interactions using tandem 
lipid-domains that are commonly used as biosensors, we decided to investigate the 
binding of single-copy LBDs, which is the most common configuration present in 
cellular proteins. Cell lysates expressing 1xPABD or 1xPH were prepared and subjected 
to analyses as described above. Specific pulldown of each LBD by its expected target 
lipid was observed (Fig. IV. 7A-D). These LBDs showed a colocalization of 55-60% with 
their respective vesicles (Fig. IV.7E-G, confirming specific lipid-protein interaction. 
We also tested 1xFYVE but could not detect any interaction with PI(3)P. This 
consistent with the previously reported lack of monomeric Hrs-FYVE binding to PI(3)P 
in live cell imaging experiments (Gillooly, Morrow et al. 2000), and the requirement of 
Hrs-FYVE dimerization for PI(3)P recognition (Gillooly, Morrow et al. 2000; Hayakawa, 
Hayes et al. 2004).  
Next we examined the assembly behavior of monomeric LBDs, in order to 
compare them to their tandem dimeric counterparts. Most of the vesicles (Fv ≈ 0.9) were 
occupied by 1xPABD within 2 min of cell lysate loading (Fig. IV. 8A) indicating a fast 
binding rate. Single-vesicle fluorescent traces revealed transient binding of 1xPABD, as 
seen by many short-lived binding-dissociation events in a single movie (Fig. IV. 8B). 
Photobleaching step analysis indicated that the distribution of NGFP for 1xPABD was up 
to five copies per vesicle and did not change markedly over incubation time (Fig. IV. 
8C). These results are in contrast to those for 2xPABD, which displayed only stable 
binding events (Fig. IV. 5D,E), higher NGFP over time, and slower rate of vesicle 
occupancy. The dimeric and monomeric PABD were present at a similar level in cell 
lysates, as determined by western blotting (data not shown). 
 The monomeric PH sensor also had a faster rate of vesicle occupancy (Fig. IV. 
8A) compared to 2xPH (Fig. IV. 5A). Again, expression levels of the monomeric and 
dimeric PH were comparable. Additionally, only transient binding events were observed 
for 1xPH (Fig. IV. 8D), with a dissociation rate of 2.33 ± 0.3 sec-1 (Fig. IV. 8E). 
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Consistent with these short-lived binding events, 1xPH was found to bind PIP2 only at 1 
copy per vesicle. We measured transient binding at two different laser intensities and 
obtained the same results, confirming that the lifetime and photoblinking of GFP 
emission did not contribute to koff determination (Fig. IV. 8D,E).  These monomeric 
LBDs did not oligomerize by themselves, as shown by anti-GFP pull-down followed by 
photobleaching analysis (Fig. IV. 8F,G).  
 Overall, our results suggest that tandem LBDs bind lipid vesicles at a slower rate 
but more stably and at higher copy numbers than their monomeric counterparts. 
 
IV. 3. 4. Assay applicability to protein kinase Akt 
After validating the versatility and specificity of our assay using LBDs, we 
deemed it necessary to explore the applicability of the assay to intact proteins. To that 
end, we decided to pursue Akt, a protein kinase of vast biological significance. Akt 
contain a PH domain that binds to PIP3 with nanomolar affinity (James, Downes et al. 
1996; Frech, Andjelkovic et al. 1997; Rowland, Gong et al. 2012). We expressed GFP-
tagged full-length Akt in HEK293 cells and observed its specific pulldown by 
immobilized PIP3 vesicles (Fig. IV. 9A,B), with ~ 47% of Akt colocalizing with the 
vesicles (Fig. IV. 9E,G). We further investigated the PH domain of Akt, in order to make 
comparisons with full-length Akt. Specific pull-down of Akt-PH by PIP3 vesicles was 
observed (Fig. IV. 9C,D), with 53% of GFP signals colocalizing with the vesicles (Fig. 
IV. 9F,G). 
 Next, we determined the assembly properties of Akt and Akt-PH on PIP3 vesicles. 
Akt-PH association with vesicles occurred very rapidly, and within 2 min of lysate 
loading 90% of the vesicles were bound (Fig. IV. 10A black line). In contrast, only ~40% 
of vesicles were occupied by full-length Akt even after 30 min incubation (Fig. IV. 10A 
gray line). Interestingly, Akt binding seemed highly stable as revealed by the single-
vesicle traces (Fig. IV. 10B). Additionally, we found that most bound vesicles had one or 
two copies of Akt irrespective of the lysate incubation time (Fig. IV. 10C). In contrast, 
single-vesicle fluorescent traces of Akt-PH revealed both stable and transient interactions 
between the domain and the lipid (Fig. IV. 10D), and the number of molecules per 
vesicle, NGFP, increased with the incubation time (Fig. IV. 10E). Akt and Akt-PH were 
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present at similar levels in the cell lysates as confirmed by Western blotting (data not 
shown). GFP-Akt by itself was monomeric, as shown by photobleaching analysis 
following anti-GFP pull-down (Fig. IV. 10F).  
We wondered if the difference in binding behavior between Akt and its PH 
domain could be due to intra-molecular interactions within Akt. Indeed, it has long been 
speculated that activation of Akt, primarily through membrane recruitment (via PIP3) and 
phosphorylation on T308 and S473, involves conformational change of the protein. An 
extension of that speculation is that Akt membrane association is influenced by its 
phosphorylation or activation state. We compared serum-starved and serum-stimulated 
cells for the analysis of Akt-PIP3 interaction, but did not observe any difference (data not 
shown). However, it was possible that only a small fraction of Akt was activated in cells 
upon serum stimulation. To unequivocally examine a possible role of phosphorylation 
(and thus activation) of Akt on its lipid binding properties, we created the following 
nonphosphorylatable and phosphomimetic mutants of Akt and analyzed their binding to 
PIP3 vesicles: T308A/S473A, T308D/S473D, T308A/S473D, and T308D/S473A. As 
shown in Figure IV. 11A,B, all the mutants bound and colocalized with PIP3 to a similar 
extent. These results suggest that phosphorylation of T308 and S473 does not impact Akt 
binding to PIP3. This conclusion is surprising and important, as it disproves a long-held 
model of Akt activation. 
  
IV. 4. Discussion 
We have developed a new approach to study lipid-protein interactions that allow 
acquisition of kinetic parameters and detection of distinctive assembly properties in crude 
cell extracts. We first demonstrated the versatility of our assay to detect specific binding 
of several LBDs to their lipid target, followed by the application to a full-length protein 
binding to its lipid target. A distinctive advantage of our approach is that it addresses 
proteins expressed in human cell lines and the assay is conducted in a more physiological 
context where unknown components are present in the cell extract.   
 The single-molecule fluorescence and CK filtration allowed comprehensive 
understanding of assembly mechanisms of the lipid-binding domains and protein. We 
were able to monitor each binding and unbinding event of LBDs to single immobilized 
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vesicles and discovered novel and distinct assembly properties of the three common 
domains present in lipid binding proteins: PH, FYVE and PABD in their monomeric and 
dimeric form, binding to PIP2, PI(3)P and PA respectively.  The monomers for all LBDs 
displayed transient binding occurring at different dissociation rates. The difference 
between the monomers could result from the chemical and structural properties of lipid-
protein interaction or could occur as an effect of other proteins present in the cell extract 
competing for the phospholipid binding. At this point, we cannot distinguish between the 
two. A striking result was that tandem LBDs displayed higher stability in terms of their 
residence time on the lipid vesicles likely due to two lipid-binding pockets. 2xPABD 
shows only stable interaction and could assemble up to nine copies per vesicle. 
Interestingly, 2xPH shows stable and transient interactions, but the distribution of copies 
per vesicle did not change over time. This may be explained by faster dissociations 
events maintaining this distribution, as evidenced by binding-unbinding events observed 
in the single-molecule fluorescence traces. Similar to 2xPH , tandem FYVE showed 
transient and stable binding characteristics. We propose that 2xFYVE sensor by itself 
shows transient interaction with PI(3)P, and its binding becomes stable when it 
encounters more copies of itself during the lysate incubation period. Additionally, this 
suggests a spatial rearrangement of the bound proteins and lipids on the vesicle resulting 
in formation of membrane nanodomains. These nanodomains could be small clusters of 
many 2xFYVE and PI(3)P lipids. This hypothesis is also supported by the inability of 
monomer FYVE to show PI(3)P binding in our assay, most likely due to very short-lived 
and unstable interactions beyond the scope of our measurement.  
We observed differences in binding behavior between two different PH domains: 
the PH domain of PLCδ and of Akt. PLCδ-PH shows only transient interactions with a 
dissociation rate of 2.33 ± 0.3 sec-1. This rate is consistent with its biological function of 
detecting the lipid PIP2 but rapidly dissociate to allow subsequent cleavage by the 
catalytic domain of PLCδ to produce inositol 1,4,5-trisphosphate and diacylglycerol. On 
the other hand, the PH domain of Akt bound both transiently and stably to its target lipid 
PIP3. In this case, it may be beneficial for Akt to have a longer residence time on the 
membrane to allow the protein kinases, such as PDK1 and mTORC2, to bind and 
phosphorylate Akt on the membrane before it is dissociates. 
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We used Akt as model system, validating that our assay can be used with full-
length proteins expressed in cell lysates. We were also able to compare the binding 
properties of full-length Akt and its isolated PH domain. Our results indicate a striking 
difference in binding kinetic and binding dynamic between full-length Akt and its 
isolated PH domain. To our knowledge, such a difference in the assembly properties and 
binding between Akt and its isolated PH domain has not been reported before (Frech, 
Andjelkovic et al. 1997), and could be possible because of the single-molecule resolution 
in our lipid-binding assay. 
It has been proposed that inactive Akt is in a conformation where the PH domain 
is protected from binding to the lipid (Calleja, Alcor et al. 2007), and this configuration 
may change due to regulatory proteins or post-translational modification. Our data 
indicates that phosphorylation at T308 and S473 sites do not affect Akt binding to PIP3. 
These results challenge the model where phosphorylation plays a key role in regulating 
membrane recruitment of Akt, and indicates that other regulatory proteins or different 
posttranslational modifications are playing a key role in this process. 
Further development of this assay, such as an extension to large macromolecular 
complexes interacting with signaling lipids, and coupling with microfluidic devices, high-
throughput technologies, and single cell sensitivity, will allow the investigation of lipid-
protein interactions at a new scale. 
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IV. 5. Figures 
 
Figure. IV. 1. Detection of lipid-protein interactions in crude cell lysates.  
(A) Schematic of the single-molecule lipid-protein interaction assay. (B) Single-molecule 
TIRF images of different vesicles (DiD, shown in top row) and the corresponding 
2xFYVE (GFP, shown in bottom row). (C) Quantification of 2xFYVE pull-down by 
different lipid vesicles (D) Single-molecule TIRF images of different vesicles (DiD, 
shown in top row) and the corresponding 2xPABD (GFP, shown in bottom row).  
(E). Quantification of 2xPABD pull-down by different lipid vesicles. (F) Single-molecule 
TIRF images of different vesicles (DiD, shown in top row) and the corresponding 2xPH 
(GFP, shown in bottom row) (G) Quantification of 2xPH pull-down by different lipid 
vesicles. Error bars depict standard deviation of the mean across 10 or more imaging 
areas. Scale bar is 10µm.  
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Figure. IV. 2. Number of DiD molecules per vesicle. Vesicles (containing Biotin-PE) 
where captured on the surface via biotin-NeutrAvidin interaction. Number of DiD 
molecules was determined by fluorescent photobleaching analysis after laser excitation at 
647 nm.  Most vesicles have 6-8 DiD molecules per vesicle. 
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Figure. IV. 3. Colocalization of tandem LBDs with lipid vesicles. (A-C) TIRF images 
show the overlay of 2xFYVE, 2xPABD, and 2xPH with PI(3)P, PA, and PIP2 vesicles, 
respectively. Overlay from the same region is shown in top rows and from different 
regions is shown in bottom rows. (D) Percentage colocalization of 2FYVE, 2xPABD, and 
2xPH to PI(3)P, PA, and PIP2 vesicles, respectively, from same and different regions. 
Error bars depict standard deviation of the mean across 10 or more imaging areas. Scale 
bar is 10µm.  
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Figure. IV. 4. Framework for data acquisition and analysis. (A) Single molecule 
fluorescent traces depicting DiD labeled vesicle (red line, 647 nm excitation) and GFP 
signal (green line, 488 nm excitation). (B-C) Chung-Kennedy filtration algorithm: 
Intensity histogram of GFP fluorescence before (B) and after CK filtration (C), for 
calculating number of photobleaching steps. (D) Visualization of 6 photobleaching steps 
(red line) after CK filtration. Raw single-molecule trace (green) over-imposed with trace 
generated by CK filtration (red line). 
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Figure. IV. 5. Assembly properties of tandem LBDs on lipid vesicles. (A) Time course 
of 2xFYVE, 2xPABD, and 2xPH binding to lipid vesicles. (B) Single-molecule TIRF 
images of 2xFYVE bound to PI(3)P vesicles from three different incubation times to 
show increasing intensity and number of GFP spots.  Single-molecule fluorescence traces 
show the increase in total intensity along with stable and transient binding properties seen 
for 2xFYVE. (C) Assembly plot depicts an increase in number of 2xFYVE copies with 
longer incubation time. Example of 1, 2 and 4 copies are shown in (B). (D) Single-
molecule TIRF images of 2xPABD bound to PA vesicles obtained from three different 
incubation times to show increasing intensity of each GFP spot. This can also be seen in 
the single-molecule fluorescent traces with higher total intensity. (E) Assembly plot 
depicts an increase in number of 2xPABD copies with longer incubation time. Example 
of 1, 4, and 9 copies are shown in (D). (F) Single-molecule fluorescent traces show 
examples of 1, 2, and 3 copies, taken at three different incubation times. (G) Assembly 
plot shows that the number of 2xPH copies do not change over the incubation time. Scale 
bar is 5µm. 
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Figure. IV.  6. Stoichiometry of tandem LBDs. (A-C) Distribution of fluorescent 
photobleaching steps for 2xFYVE, 2xPABD, and 2xPH, respectively. Tandem LBDs 
were captured from cell lysate using biotinylated antiGFP antibody.  
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Figure. IV.  7. Specific binding and colocalization of single-copy LBDs. (A) Single-
molecule TIRF images of different lipid vesicles (DiD, shown in top row) and the 
corresponding 1xPABD (GFP, shown in bottom row). (B) Quantification of 1xPABD 
pull-down by different lipid vesicles. (C) Single-molecule TIRF images of different lipid 
vesicles (DiD, shown in top row) and the corresponding 1xPH (GFP, shown in bottom 
row). (D) Quantification of 1xPH pull-down by different lipid vesicles. (E-F) TIRF 
images show the overlay of 1xPABD with PA vesicles and of 1xPH with PIP2 vesicles, 
respectively. Overlay from the same region is shown in top rows and overlay from 
different regions is shown in bottom rows. (G) Percentage colocalization of 1xPABD and 
1xPH to PA and PIP2 vesicles, respectively, from same and different and regions. Error 
bars depict standard deviation of the mean across 10 or more imaging areas. Scale bar is 
10µm. 
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Figure. IV.  8. Assembly properties of single-copy LBDs on lipid vesicles. (A) Time 
course of 1xPABD and 1xPH binding to lipid vesicles. (B) Single-molecule fluorescent 
traces of 1xPABD bound to PA vesicles to show examples of 1, 2, and 3 copies per 
vesicle.  (C) Assembly plot shows that the number 1xPABD copies per vesicle do not 
change with longer incubation time. (D) Single-molecule fluorescent traces of 1xPH 
bound to PIP2 to show transient binding events. The two traces correspond to two 
different laser intensities (20 mW and 5 mW). (E) Dwelltime histogram of 1xPH 
molecules fitted to exponential decay to give off-rate of 2.33 ± 0.3 sec-1.  
(F-G) Distribution of fluorescent photobleaching steps for 1xPABD and 1xPH, 
respectively. GFP-LBDs were captured from cell lysate using biotinylated antiGFP 
antibody. 
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Figure. IV.  9. Assay applicability to protein kinase Akt. (A) Single-molecule TIRF 
images of several vesicles (GFP, shown in top rows) and the corresponding Akt (GFP, 
shown in bottom row). (B) Quantification of Akt pull-down by different lipid vesicles. 
(C) Single-molecule TIRF images of several vesicles (DiD, shown in top rows) and the 
corresponding Akt-PH (GFP, shown in bottom row). (D) Quantification of Akt-PH pull-
down by different lipid vesicles. (E-F) TIRF images show the overlay of Akt (E) and 
Akt-PH (F) with DiD-labeled PIP3 vesicles. Overlay from the same region is shown in 
top rows and overlay from different regions is shown in bottom rows. (G) Percentage 
colocalization of Akt and Akt-PH to PIP3 vesicles, from same and different regions. Error 
bars depict standard deviation of the mean across 10 or more imaging areas. Scale bar is 
10µm. 
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Figure. IV. 10. Assembly properties of Akt and Akt-PH. (A) Time course of Akt and 
Akt-PH binding to PIP3 vesicles. (B) Representative single-molecule fluorescence traces 
of Akt bound to PIP3, showing 1 and 2 copies per vesicle.  (C) Assembly plot shows that 
the number of Akt copies per vesicle do not change with incubation time. (D) Single-
molecule fluorescent traces for Akt-PH show an increase in total intensity along with 
stable and transient binding events. (E) The assembly plot depicts an increase in number 
of Akt-PH copies with increasing lysate incubation time. Example of 1, 3, and 4 copies 
per vesicle are shown in (D). (F) Distribution of fluorescent photobleaching steps for Akt. 
Akt was directly captured from cell lysates using a biotinylated anti-GFP antibody. 
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Figure IV. 11. T308 and S473 phosphorylation sites do not regulate Akt binding to 
PIP3. (A) Comparision of Akt double mutants on T308 and S473 (DD, AA, AD, and DA 
respectively) binding to PIP3 vesicles (B) Percentage colocalization of GFP-Akt double 
mutants to PI(3)P vesicles from same and different regions. Error bars depict standard 
deviation of the mean across 10 or more imaging areas.  
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